

Review

A Narrative Review of Non-Pharmacological Strategies for Managing Sarcopenia in Older Adults with Cardiovascular and Metabolic Diseases

Theocharis Ispoglou , Oliver Wilson, Deaglan McCullough , Luke Aldrich, Panagiotis Ferentinos, Gemma Lyall, Antonios Stavropoulos-Kalinoglou , Lauren Duckworth, Meghan A. Brown, Louise Sutton, Alexandra J. Potts , Victoria Archbold, Jackie Hargreaves and Jim McKenna 

Carnegie School of Sport, Leeds Beckett University, Leeds LS6 3QQ, UK

* Correspondence: t.ispoglou@leedsbeckett.ac.uk

Simple Summary: This article explores the relationship between sarcopenia, cardiovascular disease and metabolic diseases. The authors suggest non-drug treatments such as exercise, dietary modifications and behavioural interventions as potential strategies to help older adults manage these conditions. This review highlights the importance of combining strength and aerobic training and adopting comprehensive nutritional strategies. Additionally, the authors propose integrating behavioural science to help people adopt these lifestyle changes. Further research is needed to determine the most effective treatments and ways to make these changes easier for people to adopt. Overall, a comprehensive approach is required to address sarcopenia in older adults with cardiovascular and metabolic diseases.



Citation: Ispoglou, T.; Wilson, O.; McCullough, D.; Aldrich, L.; Ferentinos, P.; Lyall, G.; Stavropoulos-Kalinoglou, A.; Duckworth, L.; Brown, M.A.; Sutton, L.; et al. A Narrative Review of Non-Pharmacological Strategies for Managing Sarcopenia in Older Adults with Cardiovascular and Metabolic Diseases. *Biology* **2023**, *12*, 892. <https://doi.org/10.3390/biology12070892>

Academic Editors: Guo-Chang Fan and Maurizio Forte

Received: 3 April 2023

Revised: 12 June 2023

Accepted: 13 June 2023

Published: 21 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: This narrative review examines the mechanisms underlying the development of cardiovascular disease (CVD) and metabolic diseases (MDs), along with their association with sarcopenia. Furthermore, non-pharmacological interventions to address sarcopenia in patients with these conditions are suggested. The significance of combined training in managing metabolic disease and secondary sarcopenia in type II diabetes mellitus is emphasized. Additionally, the potential benefits of resistance and aerobic training are explored. This review emphasises the role of nutrition in addressing sarcopenia in patients with CVD or MDs, focusing on strategies such as optimising protein intake, promoting plant-based protein sources, incorporating antioxidant-rich foods and omega-3 fatty acids and ensuring sufficient vitamin D levels. Moreover, the potential benefits of targeting gut microbiota through probiotics and prebiotic fibres in sarcopenic individuals are considered. Multidisciplinary approaches that integrate behavioural science are explored to enhance the uptake and sustainability of behaviour-based sarcopenia interventions. Future research should prioritise high-quality randomized controlled trials to refine exercise and nutritional interventions and investigate the incorporation of behavioural science into routine practices. Ultimately, a comprehensive and multifaceted approach is essential to improve health outcomes, well-being and quality of life in older adults with sarcopenia and coexisting cardiovascular and metabolic diseases.

Keywords: aerobic training; behaviour change; cardiovascular disease; metabolic diseases; nutrition; obesity; resistance training; sarcopenia

1. Introduction

Worldwide, the main reason for all-cause mortality is attributed to non-communicable diseases, namely, cardiovascular disease (CVD) and metabolic diseases (MDs) [1]. CVD refers to conditions affecting the heart and blood vessels, such as coronary artery disease, heart failure and hypertension [2]. MDs refer to disorders of processing nutrients and the use of energy. These conditions can include diabetes, obesity and metabolic syndrome,

among others [3]. Both CVD and MDs can have serious consequences, including heart attacks, stroke and organ damage [2,3]. CVD remains the leading cause of death worldwide [4]. Moreover, a recent report by the European Society of Cardiology demonstrated that among 56 countries, the prevalence of CVD was accompanied by a substantial economic cost, and the rise in MDs such as obesity and diabetes represented the biggest challenge in further reducing the CVD burden [5]. CVD and MDs are often caused by a combination of genetic, lifestyle and environmental factors [6,7] with older adults being more susceptible to CVD and death [8]. Considering that health behaviours, such as physical inactivity and poor nutrition, are linked to poor outcomes in CVD [7], it is important to manage these conditions through everyday lifestyle changes.

Sarcopenia is another highly prevalent condition in older adults; it is recognised as a muscle disease [9] and is characterised by the loss of muscle mass, strength and function [10]. Although sarcopenia is largely attributed to ageing (i.e., primary sarcopenia), other causes (e.g., disease and physical inactivity) may contribute to sarcopenia (i.e., secondary sarcopenia) [10]. Furthermore, in the revised consensus of the European Working Group on Sarcopenia in Older People 2, acute sarcopenia (likely due to acute illness or injury) and chronic sarcopenia (likely due to long-term conditions such as inflammatory diseases) are identified as new subcategories meriting further attention when designing interventions to better manage muscle-related diseases [10]. Sarcopenia can lead to decreased mobility, increased frailty, increased risk of falls and fractures and other harmful outcomes such as functional decline, increased hospital stay and mortality [11,12]. Furthermore, sarcopenia is associated with poorer mental health outcomes such as depression [13]. Although the pathogenesis of sarcopenia is not fully understood, it is considered a multifactorial process, involving a reduction in hormones that help with muscle mass maintenance, decreased physical activity, anabolic resistance (i.e., changes in the body's ability to use proteins to build and maintain muscle tissue), nutritional status, inflammation, mitochondrial dysfunction [14,15] and the presence of diseases (e.g., systemic diseases such as diabetes and metabolic syndrome) that can further affect muscle mass and strength [16]. To prevent or manage sarcopenia, it is important to engage in regular physical activity and eat a balanced diet that includes enough protein to support muscle growth and maintenance [17]. Recent evidence has also highlighted a longitudinal association between a higher incidence of CVD with sarcopenia and probable sarcopenia in middle-aged and older adults [18]. Therefore, any efforts to prevent and better manage sarcopenia may be an effective means for reducing the incidence of CVD and improving health and quality of life in older adults with CVD and/or MDs. Collectively, the evidence presented above suggests that sarcopenia and CVD/MDs are associated with ageing, while modifiable risk factors such as a sedentary lifestyle and an unhealthy diet increase the risks associated with these conditions. Treating and managing most cases of sarcopenia—a concern for many clinical and non-clinical groups—may involve lifestyle changes to optimise physical activity levels and nutritional intake, benefitting patients with CVD and MDs by reducing health complications and improving overall health. Risk factors for sarcopenia are depicted in Figure 1.

As sarcopenia is multifaceted, it affects multiple physiological systems, meaning that insights and perspectives can be drawn from different disciplines to provide a comprehensive and holistic approach to treatment. For example, physical activity interventions may be ineffective in older populations simply because older adults might not be able to adhere to these interventions due to a host of factors that may include physical limitations, chronic illnesses, obesity, a lack of social support and low socioeconomic status [19]. Similarly, the effectiveness of nutritional interventions may be negatively influenced by further factors, including underdeveloped professional support, physical restrictions, unhelpful family influences and difficulties in changing eating habits [20]. Therefore, it is important that bespoke interventions, designed to cater to the specific needs of any older population, integrate powerful elements of behavioural modification and implementation aspects to enhance intervention effectiveness. Importantly, every approach may vary depending on

the individual's specific needs and circumstances, as much as it can be influenced by the availability of resources and the preferences of healthcare teams [21,22].




Figure 1. Risk factors for sarcopenia. The figure was created with [BioRender.com](https://www.biorender.com) (Accessed on 1 February 2023).

The primary aims of this narrative review are twofold: (a) to delineate the mechanisms that contribute to the pathogenesis of CVD/MDs, with an emphasis on the shared risk factors and reciprocal relationship between sarcopenia and CVD/MDs, and (b) to propose non-pharmacological interventions, such as physical activity, dietary modifications, behavioural interventions and implementation strategies, as potential approaches to mitigate sarcopenia in patients with CVD/MDs.

2. Physiological Factors That Underpin Sarcopenia, Cardiovascular and Metabolic Diseases

2.1. The Role of Mitochondria in Cellular Processes and Substrate Utilisation and Its Implications for Sarcopenia, Insulin Resistance and Age-Related Muscle Dysfunction

Metabolic diseases are often underpinned by the interrelated pattern of metabolic abnormalities such as atherogenic dyslipidaemia, insulin resistance (hyperglycaemia and hyperinsulinaemia), abdominal obesity and inflammation [23,24]. In this following section, the potential mechanisms that intrinsically link skeletal muscle dysfunction, MDs and ageing are explored.

Mitochondria are crucial for diverse cellular processes, including substrate utilisation, calcium homeostasis, cell proliferation, quality control (e.g., fission, fusion and mitophagy) and apoptosis [25,26]. Mitochondrial dysfunction compromises cell homeostasis and exercise capacity and is a central mediator in the pathogenesis of sarcopenia [25]. However, the molecular basis of the relationship between mitochondrial dysfunction and sarcopenia is multifactorial and poorly understood. Human muscle biopsies have established that the mitochondrial content, measured directly using transmission electron microscopy, is lower in the skeletal muscle of older individuals than in young individuals [27,28], possibly due to differences in the size [29] or number of (subsarcolemmal) mitochondria [28]. As peak oxygen uptake is strongly related to skeletal muscle mitochondrial content in older individuals [30], a reduced content may restrict the performance of daily living tasks. Mitochondrial enzyme activities in β -oxidation (e.g., β -hydroxyacyl-CoA dehydrogenase),

tricarboxylic acid (e.g., citrate synthase) and respiratory chain pathways (e.g., succinate dehydrogenase and cytochrome C oxidase) are also lower in the skeletal muscle of older individuals than in young individuals [28,31–33]. These findings are accompanied by a lower in vivo oxidative capacity [27,34] and the uncoupling of adenosine triphosphate resynthesis to oxygen consumption [35]. The dual inferiorities of lower mitochondrial content and oxidative capacity are supported by a reduced expression of genes in the tricarboxylic acid and respiratory chain pathways [36,37], mitochondrial ribosomes [36] and in vivo mitochondrial protein synthesis rates with age [38].

Middle-aged patients with obesity and type II diabetes (TIID) also have lower mitochondrial content and size in their skeletal muscle compared to lean age-matched controls, measured using transmission electron microscopy [39–41]. This is accompanied by lower in vitro oxidative capacity and respiratory enzyme activity [39–41]. Furthermore, in vivo oxidative capacity is impaired in older patients with TIID [42,43], which is linked to lower basal and maximal mitochondrial respiration compared to age-matched controls [43]. Thus, lower mitochondrial function is not only important in the development of sarcopenia but is also suggested to be a contributing factor to the development of insulin resistance [44]. However, some studies that used transmission electron microscopy [45] or citrate synthase activity as a strong biomarker of mitochondrial content [46] reported no difference in the mitochondrial content between middle-aged and older patients with TIID and controls [47,48]. As a result, it is unclear whether a lower mitochondrial content occurs in human skeletal muscle with insulin resistance. Nevertheless, evidence suggests that the skeletal muscle mitochondrial content is correlated with markers of insulin resistance in ageing [49] and TIID [39–41], but causation cannot be assumed. Lower mitochondrial respiratory function in the skeletal muscle of patients with TIID compared with controls has also been reported in some, but not all studies, as previously reviewed [50]. The reason for this discrepancy remains unclear, but it may be related to differences in measurement techniques, the normalisation of the respiratory function to the mitochondrial content and/or the physical activity status of the participants [50].

Mitochondria have numerous functions, including the generation of adenosine triphosphate from the oxidation of carbohydrate and fat. Lipid droplets, which store fatty acids such as triacylglycerol, can be in physical contact with the mitochondrial membrane in the subsarcolemmal and intermyofibrillar regions of human skeletal muscle [51]. The attachment of lipid droplets to mitochondria facilitates the channelling of lipid droplet-derived fatty acids to the mitochondria for oxidation based on the energy needs of the cell [52]. Compared to younger individuals, the intramyocellular lipid droplet size and content are elevated in older adults [28] and in individuals with TIID compared to controls [45,51]. Region-specific lipid droplet morphology may be important in ageing and MDs, as the subsarcolemmal lipid droplet size is larger in older individuals [28] and in patients with TIID compared to controls [45,53]. It is worth noting the excessive accumulation of very large subsarcolemmal lipid droplets in muscle fibres with a low subsarcolemmal mitochondrial content in patients with TIID. This may be important, as larger subsarcolemmal lipid droplets have been linked to reduced insulin sensitivity [45,54].

Increased plasma fatty acid uptake and decreased fatty acid oxidation may contribute to the accumulation of intramuscular lipid droplets [50]. A lower mitochondrial content correlates with lower fasting fat oxidation [41], and a negative association between age and fatty acid oxidation in human skeletal muscle primary myotubes has been reported [55]. This finding is in line with lower rates of whole-body fat oxidation rates observed at rest [56,57] and during endurance exercise at the same absolute and relative exercise intensity in older individuals compared to young individuals [58]. Alterations in substrate utilisation with ageing are distinct from those in obesity and TIID. In individuals with obesity, fat oxidation is lower under fasting conditions compared to lean controls [59]. However, the insulin-mediated inhibition of fat oxidation and a consequent switch towards carbohydrate oxidation are impaired in obesity and TIID [59,60]. Individuals with obesity and impaired glucose tolerance exhibit higher rates of fat oxidation and blunted

increases in carbohydrate oxidation when transitioning from rest to exercise compared to controls [61,62]. Mitochondria are thought to be functional components in adapting substrate utilisation to substrate availability and energetic demand, termed metabolic flexibility [63]. However, metabolic inflexibility may occur when there is a mismatch between fatty acid supply, uptake and oxidation in skeletal muscle [64,65], leading to the accumulation of fatty acid metabolites that can cause insulin resistance and potentially mitochondrial dysfunction [66].

2.2. *The Role of Lipid Metabolism and Adipose Tissue Dysfunction in Metabolic Disorders and Cardiovascular Disease*

In healthy adipose tissue, excess energy is primarily stored in subcutaneous adipose tissue. However, lipid storage can also occur in other tissues, including visceral adipose tissue visceral adipose tissue, which can lead to inflammation over time. With dysfunctional adipose tissue as observed with MDs and ageing [67], there may be a lipid spillover, which is deposited as visceral adipose tissue and a variety of organs, including muscle tissue [68]. Mendelian randomisation has demonstrated a causal effect of visceral adipose tissue on MDs (hypertension, heart attack/angina, T2D and hyperlipidaemia) by identifying 102 novel loci (i.e., genes) associated with visceral adipose tissue [69]. Visceral adipose tissue has a higher lipolytic rate compared to subcutaneous adipose tissue, which is attributed to the heightened effect of pro-lipolytic catecholamines and reduced effect of anti-lipolytic insulin [68,70]. Consequently, increased lipolysis in visceral adipose tissue leads to a higher flux of free fatty acids to the liver, ultimately resulting in the elevated synthesis of very-low-density lipoprotein and hepatic insulin resistance [70]. Increased levels of very-low-density lipoprotein and chylomicrons create greater competition for lipoprotein lipase, allowing for greater cholesterol ester transfer protein activity with low-density lipoprotein (LDL). Hepatic lipase has a higher affinity for the now triglyceride-enriched LDL, triggering small-dense LDL (sdLDL) production [71]. The prevalence of sdLDL particles underpins atherogenic dyslipidaemia along with high triglyceride levels, and low levels of high-density lipoprotein cholesterol (HDL-C) and are highly associated with increased CVD risk [23,24].

Lipoproteins come in different sizes, densities and lipid content [72]. Two phenotypes, A and B, have been identified to indicate CVD risk [73]; phenotype A has more large and buoyant LDL (lbLDL), while phenotype B has more sdLDL [72,73], which is associated with low HDL-C, high triglycerides levels and metabolic diseases [74,75]. Numerous epidemiological studies have confirmed the reliability of LDL-C as an indicator of CVD risk and that LDL is a causative factor of CVD [76–78]. In cases where there is discordance between the two measures, the LDL particle (LDL-P) number may better estimate the CVD risk than LDL-C [79]. When LDL-P is greater than LDL-C, it shows a greater association with CVD events and markers of metabolic health [79,80]. Circulating sdLDL particles have a higher risk of CVD events compared to larger and buoyant lbLDL particles [72,74] because an sdLDL particle has less cholesterol than an lbLDL particle, which leads to a greater number of sdLDL particles when cholesterol is equal [80].

Elevated triglyceride concentrations are associated with at least a 2-fold increase in CVD and mortality risk [81,82]; however, adjusting for HDL-C levels reduces this risk [76]. Although higher HDL-C levels are associated with reduced CVD risk [76,77], therapies that increase HDL-C do not reduce CVD risk [83,84]. HDL, through reverse cholesterol transport, carries cholesterol to the liver for removal and exerts anti-inflammatory effects on peripheral tissues, including arterial lesions [85,86]. Cholesterol efflux from macrophages may offer atheroprotection and is inversely associated with CVD independent of HDL-C concentrations [87,88]. Therefore, the functionality of HDL rather than HDL-C may have a more causal relationship with CVD [89]. Exercise increases HDL-C concentrations in a dose-response manner and has the potential to improve the anti-inflammatory effects and cholesterol efflux capacity of HDL [90]. Triglycerides alone are unlikely to cause atherosclerosis; however, they may act as a marker for triglyceride-rich lipoproteins (TRLs)

rich in cholesterol, which are more efficient contributors to atherosclerosis [91,92]. For example, TRLs can enter the arterial intima and undergo direct phagocytosis by macrophages, contributing to foam cell formation, inflammation and atherosclerotic plaques [91,92]. In addition to being involved in lipid storage, mobilisation and lipoprotein metabolism, adipocytes are also endocrine tissues that release cytokines and adipokines [93]. An increase in visceral adipose tissue and atherogenic dyslipidaemia leads to a pro-inflammatory state characterised by elevated C-reactive protein and tumour necrosis factor- α concentrations that are associated with sarcopenia and MDs [94,95]. Given these mechanisms, practitioners should prioritise interventions that can improve HDL functionality, reduce visceral adipose tissue, and improve atherogenic dyslipidaemia, such as exercise and dietary modifications.

2.3. Dysfunctional Cellular Metabolism and Insulin Resistance: Implications for Cardiovascular and Metabolic Diseases

This pro-inflammatory state and elevated supply of free fatty acids to the vascular tissues lead to degenerative changes in the extracellular matrix, leading to endothelial insulin resistance and dysfunction and ultimately hypertension [96]. Insulin resistance of the endothelial cells increases vascular tone due to the disruption of the balance of vasodilators (nitric oxide, prostacyclin) and vasoconstrictors (endothelin, angiotensin), contributing to vascular stiffness [97] and potentially reducing insulin and nutrient delivery to the muscle fibres [98]. Diminished insulin PI3K/Akt signalling in vascular tissue leads to a reduction in nitric oxide production via blunted endothelial nitric oxide synthase action [99]. Consequently, intracellular Ca²⁺ concentrations remain elevated in vascular smooth muscle cells, allowing vascular contractions to continue, thus limiting the dilation of vascular tissues and increasing vascular tone [99]. Conversely, endothelin-1 production continues via insulin-dependent mitogen-activated protein kinase signalling, leading to vasoconstriction [100]. A reduction in tissue perfusion, such as in skeletal muscle, can lead to a reduction in insulin and nutrient availability and therefore could have consequences for the maintenance of muscle mass and blood glucose clearance with age [98]. Furthermore, along with mitochondrial dysfunction, insulin resistance and prohypertensive factors also stimulate reactive oxygen species, triggering downstream signalling that leads to vascular dysfunction and endothelium permeability, thus contributing to the development of atherosclerosis [101,102].

Dysfunctional cellular metabolism, characterised by lipotoxicity, inflammation, oxidative stress and mitochondrial dysfunction, is implicated in the development of insulin-resistant tissue [103,104], which is a key feature of CVD and MDs [105–107]. In healthy insulin-sensitive tissue, insulin binds to the insulin receptor, thus activating the key multifunctional protein kinase Akt, elevating anabolic signalling and reducing catabolic signalling [108]. The activation of Akt initiates downstream signalling, resulting in GLUT4 trafficking and fusion with the cell membrane, allowing cellular glucose uptake [109]. However, within insulin-resistant tissues, this signalling cascade is diminished due to metabolic disturbances primarily upstream of Akt, resulting in reduced glucose uptake [103,104]. Skeletal muscle is the largest tissue for insulin-induced glucose uptake, accounting for ~75% of insulin-stimulated glucose uptake [110] (although adipose tissue and the liver are also involved) [111]. Insulin resistance in adipose tissue triggers an increase in the production of free fatty acids, which can then be deposited in other tissues such as muscle and the liver [112]. Excessive intramyocellular lipid accumulation leads to the build-up of diacylglycerol and ceramide [66], impairing insulin signalling and reducing glucose uptake, glucose oxidation and glycogen synthesis while diminishing its anti-catabolic effects [104]. In summary, excessive fat storage in muscle cells disrupts normal signalling pathways, leading to reduced insulin sensitivity and impaired glucose utilisation. An increase in the supply of free fatty acids can also stimulate liver steatosis, resulting in atherogenic lipoprotein metabolism and diminished insulin stimulation causing hepatic glucose production, further increasing hyperglycaemia [113]. This in turn exacerbates hyperglycaemia, resulting in advanced glycated end products, further stimulating inflammation and the

development of MDs [114]. Ultimately, peripheral insulin resistance causes a myriad of metabolic disturbances, triggering a vicious cycle of lipotoxicity, inflammation, oxidative stress and further insulin resistance. These processes are associated with ageing and negatively impact skeletal muscle mass and quality, exacerbating MDs and reducing quality of life.

2.4. The Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Obesity-Induced Insulin Resistance and Ageing

Obesity is associated with increased mitochondrial reactive oxygen species (ROS) emission, whereas even a single high-fat meal increases ROS emission in lean healthy controls, suggesting the involvement of an elevated supply of free fatty acids in ROS production [115]. The chronically elevated production of ROS by mitochondria and other sources in skeletal muscle is associated with mitochondrial dysfunction in ageing [116] and obesity-induced insulin resistance [117], while ROS production and oxidative damage remain low in healthy individuals. However, ROS levels can be elevated when substrate delivery to the mitochondria is high, while mitochondrial adenosine triphosphate resynthesis rates are low, such as when a high-fat diet and a physically inactive lifestyle are combined [115]. Elevated ROS levels, beyond the capacity of endogenous antioxidants to scavenge the ROS, cause oxidative damage to mitochondria DNA (mtDNA) and mutations in mtDNA coding regions for respiratory chain proteins, leading to defects in respiratory chain function, the uncoupling of oxidative phosphorylation and further increases in ROS levels in a feedforward mechanism [117,118]. High ROS levels lead to the destruction of mitochondria and, if spread across the mitochondrial reticulum, cell death [119].

2.5. The Importance of Physical Activity and Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 α in Maintaining Mitochondrial Quality Control and Skeletal Muscle Health

Mitochondrial quality control in skeletal muscle involves biogenesis, fusion (exchanging components within healthy mitochondria to form an extended mitochondrial network) and fission (removing components), ultimately impacting skeletal muscle mass [120]. Peroxisome proliferator-activated receptor-gamma coactivator 1 α (PGC-1 α) is a key regulator of mitochondrial biogenesis and function and plays a role in fission/fusion [121]. PGC-1 α transcription networks are also positively associated with appendicular lean mass index and hand grip strength [36]. Consequently, a sufficient intramyocellular PGC-1 α content is important for skeletal muscle health and protection against sarcopenia [116,121]. In physically active individuals, ageing alone does not decrease the gene expression or protein content of PGC-1 α , mitochondrial fission, or fusion proteins [122,123]. Sarcopenia of human skeletal muscle is associated with the downregulation of PGC-1 α messenger ribonucleic acid and transcription signatures for PGC-1 α networks in fission and fusion compared with controls [36,124]. Similarly, the downregulation of PGC-1 α messenger ribonucleic acid [125] and lower fission and fusion protein contents have been observed in the skeletal muscle of patients with T1DM compared with controls [126]. These findings highlight the crucial role of PGC-1 α in maintaining skeletal muscle health and function and suggest its potential as a therapeutic target for age-related and metabolic disorders. Therefore, a reduction in PGC-1 α and an impairment of mitochondrial fission and fusion processes are potential contributors to both sarcopenia and MDs.

A common factor in many studies of ageing, mitochondrial dysfunction and MDs in humans is the participant's habitual physical activity status; for example, masters athletes have a greater mitochondrial content, oxidative and respiratory enzyme gene expression and activity and in vivo respiratory capacity relative to controls [30,123]. Consequently, master athletes have a well-maintained mitochondrial content and function despite their older age. Moreover, physically inactive elderly individuals retain the ability to adapt to exercise training. It is well known that muscle mass and strength can increase in the elderly following resistance-type exercise training [127]. Mitochondrial content and function also increase in older individuals following endurance-type exercise training [30,128]. This can increase the capacity to oxidise fat during exercise [129], contributing to a reduction in

visceral fat mass [130] and chronic low-grade inflammation following exercise training [131]. PGC-1 α [30] and mitochondrial fission and fusion proteins are also elevated in masters athletes, suggesting improvements in mitochondrial quality control processes following exercise training [123]. Together, the chronic responses of skeletal muscle to exercise training contribute to improved insulin sensitivity in older individuals [132]. Consequently, physical inactivity, rather than ageing, is a major contributor to the age-related decline in muscle quality [30]. Exercise is strongly indicated to improve skeletal muscle quality in older individuals to protect against the development of mitochondrial dysfunction, sarcopenia, CVD and MDs.

3. Exercise and Physical Activity Interventions

Secondary sarcopenia, associated with chronic diseases, requires multiple treatment targets. Physical inactivity, a modifiable risk factor, contributes to both the development and progression of CVD, yet it is often triggered by CVD symptoms such as dyspnoea, angina and claudication upon exertion. Lifestyle modifications, including physical activity, are important for providing non-pharmacological treatments to manage these complex disease states.

Progressive, resistance-based exercise training (RT) has been recommended by the International Clinical Practice Guidelines for Sarcopenia (ICFSR) to treat sarcopenia and improve muscle strength, muscle mass and function [133]. This approach has recently been supported by Hurst et al. [134]. However, the ICFSR review also highlighted the scarcity of high-quality evidence RT interventions in sarcopenic populations [133]. Further research is necessary to understand the impact of RT interventions on chronic CVD and sarcopenia, which often coexist and may share multiple pathogeneses [135–137].

Furthermore, the aim of exercise interventions in patients with chronic or congestive heart failure (CHF) is not only to elicit improvements in skeletal muscle parameters but also to improve the chronic disease causing or contributing to the development of sarcopenia while also improving poor overall health and quality of life [138]. High repetition, low-weight RT has been recommended for older adults to improve muscle strength [139]. In older adults, who are inexperienced in RT, significant positive adaptations have been observed in both the skeletal muscle and neuromuscular systems [140]. Additionally, aerobic-based exercise training (AT) has been proposed as a beneficial intervention for sarcopenia due to its capacity to promote mitochondrial biogenesis and insulin sensitivity while reducing oxidative stress [141].

3.1. The Potential of Combined Resistance-Based and Aerobic-Based Exercise Training for Improving Muscle and Metabolic Health in Patients with T2DM and Sarcopenia

Combining RT and AT could be beneficial for patients with T2DM and secondary sarcopenia by targeting both conditions simultaneously. For example, Tan et al. [142] combined RT and AT for a duration of six months to produce significant improvements in muscle strength and function with additional beneficial reductions in fasting insulin, glucose and glycosylated haemoglobin (HbA1c). In another study, interval AT improved lower limb muscle strength and reduced HbA1c levels [143]. More recently, RT interventions using sandbags have provided support for the effectiveness of RT in improving glycaemic control in T2DM patients with sarcopenia by reducing HbA1c levels and improving upper-body muscle strength and lean mass [144]. The improved glycaemic control can be attributed to the increase in the glucose transporter 4 (GLUT4) content, which enhances insulin transport and sensitivity [145]. Moreover, RT has also been shown to increase insulin-like growth factor 1, which plays a crucial role in muscle generation, muscle mass and muscle strength [146] and also affects insulin sensitivity. Systematic reviews have also indicated that RT can improve metabolic health in T2DM patients without sarcopenia [147]. A recent meta-analysis has demonstrated that a combination of RT and AT resulted in the greatest decrease in HbA1c in T2DM patients, followed by either RT or AT independently [148]. Therefore, the combination of RT and AT may be the most suitable intervention for metabolic disease such

as T1D. However, it is essential to note that diet-induced weight loss may have the most pronounced and positive effects on metabolic and musculoskeletal health [149]. In addition, nutritional support is necessary to maintain protein intake and prevent the deterioration of musculoskeletal health due to calorie restriction.

3.2. The Potential Benefits of Resistance and Aerobic Exercise Training for Cardiovascular Patients with Secondary Sarcopenia: Evidence from Congestive Heart Failure, Coronary Artery Disease, and Peripheral Artery Disease Studies

While AT is often recommended to treat CVD, there is a lack of research on the most suitable exercise interventions when CVD coexists with secondary sarcopenia. CHF is a late-stage condition that affects approximately 2% of the population and is characterised by significant reductions in skeletal muscle leading to sarcopenia; this reduction in muscle mass is often accompanied by reduced cardiorespiratory fitness, increased disease severity and a poor overall prognosis [150,151]. A recent systematic review of exercise-based rehabilitation in CHF patients revealed that RT alone improves lower and upper extremity muscle strength, peak oxygen uptake and 6-min walking distance, without any detrimental effects on the left ventricular parameters, when compared to usual care or an AT intervention [152]. Hence, RT may serve as a feasible strategy for improving physical function and quality of life in CHF patients who might not have the ability or willingness to participate in aerobic activities. It is important to mention that the aforementioned systematic review did not evaluate the occurrence of sarcopenia. Nevertheless, considering the age and multi-morbidities present within such a population, it is plausible to assume the presence of reduced muscle performance, muscle mass and muscle quality. An early study comparing older women with CHF to age-matched controls found that CHF patients had lower muscle strength but similar aerobic capacity [153]. Resistance training improved muscle characteristics and exercise performance in CHF patients, with skeletal muscle adaptations being the main contributor. Supporting the exercise prescription principle of specificity, this supports the idea that muscle function is more specifically affected than aerobic capacity in older CHF patients. In the same study, no improvements were observed in aerobic exercise capacity (peak oxygen uptake and minute ventilation), regardless of significant increases in citrate synthase activity, suggesting that specific AT incorporated as part of a combined exercise intervention may be more suitable for CHF patients. A subsequent study provided evidence that only a combined RT and AT programme led to improvements in both peak oxygen uptake and peripheral muscle strength, which are significant factors in the outcomes and quality of life of patients with CHF [154]. This idea has been reinforced in studies on heart failure models in both humans and rats [154–156], which have demonstrated improvements in muscle strength, cardiorespiratory fitness and overall quality of life. Heart failure has also been shown to cause a shift from fast- to slow-twitch muscle fibres, muscle atrophy, oxidative stress, reduced mitochondrial density, increased susceptibility to fatigue and increased biomarkers involved in the ubiquitin-proteasome system, which breaks down muscle proteins [135,157,158]. However, in both rat and human models, AT [157,158] and interval training [156] interventions alleviated the negative physical and molecular changes associated with CHF, thus preserving muscle function. High-intensity interval training (HIIT), in particular, has been linked to an increase in the cross-sectional area of both type I and II muscle fibres, indicating its potential benefits for patients with CHF, as per Bowen et al. [156]. According to Saitoh et al. [159], the mechanism underlying these desirable and protective adaptations involves the increased activation of PGC-1 α , which is supported by Lira et al. [160].

Sarcopenia has also been linked to major adverse cardiovascular events after surgery in older patients with coronary artery disease [161,162]. However, RT, AT, or a combination of both have been deemed safe and effective for improving muscle health, cardiorespiratory fitness and quality of life in this population [163,164]. Yamamoto et al. [163] showed that RT interventions improved exercise capacity, muscle strength and general mobility in older adults with coronary artery disease in a meta-analysis of 22 trials. Fan et al. (2021)

supported these findings but suggested that combined training methods are more beneficial than either AT or RT alone.

Peripheral artery disease typically affects peripheral system arteries and is frequently accompanied by musculoskeletal abnormalities [165] such as muscle weakness, muscle atrophy and denervation of lower limb muscles [166]. In a small randomised controlled trial, which employed strength testing and histological assessments indicated, RT improved muscle strength and brought about beneficial intramuscular adaptations such as an increase in muscle fibre area and capillary density [167]. Furthermore, a recent meta-analysis by Parmenter et al. [168] showed that RT performed at high intensities (~80% 1RM) was associated with greater walking ability in peripheral artery disease patients, while RT at all intensities improved the distance to onset of claudication.

4. Nutrition Interventions

According to He et al. [135], exercise, proper nutrition, hormone therapy and medication are effective in preventing and treating sarcopenia and CVD. Addressing sarcopenia through such modalities may prevent muscle mass, strength and function decline, maintain insulin-stimulated glucose uptake and reduce the risk of T2DM and CVD. In the following sections, an overview of nutritional strategies is provided.

4.1. Optimising Nutritional Interventions for Sarcopenia and CVD/MDs: Importance of Protein Intake and Quality

To prevent and treat sarcopenia in older adults and to address CVD and MDs, nutritional interventions emphasise appropriate energy intake and dietary protein including aspects such as quantity, quality and timing of consumption [17,169]. In older adults, the impaired muscle protein synthesis response to food and physical activity contributes to muscle mass loss and a decline in metabolic health [170]. Adequate energy and dietary protein intake, including amino acids, are necessary to support muscle growth, maintenance and reduce health risks [17,169]. Dietary proteins provide amino acids for muscle protein synthesis and glucose control, resulting in reduced triglyceride levels and potentially improve insulin response to feeding [137]. In individuals with a high body mass index, inadequate protein intake increases the risk of 'sarcopenic obesity' [171], which can increase the risk of cardiovascular-related illness, frailty and falls, and it can reduce muscle functionality. When assessing individuals with excess adiposity and other complex metabolic and lifestyle issues, the key focus of exercise and dietary strategies is often overall weight reduction [172]. However, such interventions often compromise the ability to preserve muscle mass and function due to the emphasis on achieving energy deficits. This can create a vicious cycle where older adults become weaker and less able to engage in physical activity, which is crucial for maintaining energy balance and combating obesity.

To optimise skeletal muscle health and reduce the risk of CVD/MDs, it is recommended to exceed the recommended dietary allowance (RDA) of 0.8 g/kg body mass per day for protein intake, as supported by long-term studies [169,173–175]. According to the recommendations by the European Society for Clinical Nutrition and Metabolism (ESPEN), individuals suffering from an acute or chronic disease should increase their protein intake by 50–90% (~1.2–1.5 g/kg/bm per day) above the RDA and maintain an energy intake of 25–30 kcal/kg/day [169]. For older adults, a phased protein intake of 25–30 g of protein three times a day is recommended to optimise the rates of muscle protein synthesis (MPS) [17,176–178]. This extra intake is needed because older individuals tend to be less sensitive to anabolic stimuli such as protein and prone to 'anabolic resistance' [178,179]. Studies show that the absolute protein requirement for the stimulation of muscle protein synthesis within a single meal is greater in older adults (~35 g) than in younger adults (~20 g) [180,181]. However, increasing protein intake may cause unwanted appetite loss and reduce overall nutritional intakes [182]. This has been termed as the 'protein paradox' [17], where increasing protein intake may unintentionally cause reductions in energy and protein intakes through partial energy redistribution. Interestingly, older UK adults

had low protein intake, with 85% failing to meet the minimum RDA of 1.2 g/kg/day, as per ESPEN, and only 24.6% achieved protein intakes of 25 g per meal according to the Protein 4 Life collaboration [176,183]. Therefore, it is necessary to implement population-wide strategies to boost protein intake for optimal MPS stimulation while considering cardiovascular health, with recent research focusing on protein quality and supplementation.

Branched-chain amino acids such as leucine, isoleucine and valine are effective at regulating hormones involved in food intake and glucose regulation [184,185]. Leucine, in particular, has been studied for its ability to preserve muscle mass without compromising reductions in appetite and energy intake when consumed alongside other essential amino acids (EAAs) [182,186–188]. It was demonstrated that in muscle-depleted patients with CHF, EAA supplements combined with adequate energy–protein intake improved the nutritional and metabolic status [189]. However, not all outcomes improved, possibly because the EAAs were given separately from meals, leading to increased oxidation rates, as seen with fast-acting protein sources [190]. Palatability issues when diluting EAAs in water may have also affected the compliance data. Importantly, when considering protein intake in the context of CVD, it is crucial to be mindful of the potential of high-protein diets to include red meat, processed meat and other foods high in saturated fats, which can increase serum lipid levels such as triglycerides and heighten the risk of heart disease [191]. Recent studies show that plant protein intake is associated with reduced all-cause and cardiovascular mortality, whereas animal protein intake may increase the risk of CVD mortality, as seen in previous cohort studies [192,193]. This suggests that protein sources are important for long-term health. Recent studies have also linked higher intakes of total meat and unprocessed red meat to a higher incidence of atherosclerotic cardiovascular disease, possibly due to the plasma levels of metabolites produced by gut microbiota [194]. Therefore, for managing sarcopenia in older adults with CVD/MDs, an effective approach for increasing protein intake may involve substituting animal-based protein with plant-based alternatives.

4.2. Incorporating Antioxidant and Anti-Inflammatory Foods for Sarcopenia, Cardiovascular Disease and Metabolic Disease Management and Prevention

Sarcopenia, CVD and MDs share common characteristics of oxidative stress and inflammation [195,196], with ageing increasing oxidative damage and inflammation [197,198]. In contrast, antioxidant and anti-inflammatory compounds in food and drinks can increase the antioxidant capacity and reduce inflammation. Studies [199,200] show that consuming antioxidant-rich foods such as fruits, vegetables, nuts, cacao, oils, micronutrients (e.g., selenium, magnesium, iron and vitamins A, C and E), plant-derived polyphenol-rich foods (e.g., berries and cherries) and long-chain fatty acids (e.g., omega-3 fatty acids) can help manage, treat and prevent sarcopenia in older adults aged >55 years [201]; the most promising interventions were increased fruit and vegetable consumption, tea catechins, magnesium and combined vitamin E, D and protein supplementation. Other studies support these findings, suggesting that minerals may aid sarcopenia prevention and treatment in healthy and frail older adults (>65 years) [202], whereas a higher dietary inflammatory index is associated with worse sarcopenic symptoms in older adults (>65 years) [203]. Although most evidence excludes sarcopenic individuals with specific health conditions (e.g., sarcopenic obesity), a recent study associated diets with a higher total antioxidant capacity with reduce abdominal obesity, fasting glycaemia and sarcopenia in T1D patients [199]. Among 158 healthy older adults, a potential association between increased inflammation (based on C-reactive protein levels) and slightly reduced appetite was identified [204]. It is crucial to note that while reducing oxidation and inflammation can be beneficial, these processes play an important role in physiological adaptations to exercise [205]. Given the importance of physical activity (see Section 3) in managing sarcopenia, CVD and metabolic diseases, interventions with antioxidant or anti-inflammatory foods or drinks should be carefully considered, as excessive levels may hinder exercise benefits [206]. However, some studies show that antioxidant supplementation can improve various outcomes when

combined with exercise in certain populations [207,208]. Emerging evidence suggests that omega-3 polyunsaturated fatty acids may benefit sarcopenic older adults due to their anti-inflammatory properties and anabolic effect on muscle by reducing insulin resistance and activating mTOR signalling [209]. Interestingly, older T1ID patients with sarcopenia have lower omega-3 fatty acid intake than those without sarcopenia [210]. Although few randomized controlled trials have investigated antioxidant and/or anti-inflammatory intake in sarcopenic individuals with CVD or MDs, existing evidence is promising [211,212]. Korean Red Ginseng at 3 g/day for 24 weeks significantly improved the biomarkers of sarcopenia in older adults with T1ID, especially postmenopausal women [213]. Another randomized controlled trial demonstrated that tea fortified with catechins alongside EAA supplementation and exercise for three months improved walking speed, stride length, vitamin D and total body fat mass compared to a control group in women with sarcopenic obesity [214].

4.3. The Importance of Vitamin D in Preventing and Managing Sarcopenia, Cardiovascular Disease and Metabolic Diseases in Older Adults

Vitamin D is essential for bone and muscle health; however, deficiency (often considered as serum 25-hydroxyvitamin D <50 nmol/L) affects people of all ages worldwide [215]. Older individuals are particularly susceptible due to factors such as reduced dietary intake, sun exposure, and reduced ability to synthesise vitamin D [216]. Insufficient vitamin D levels predict outcomes associated with reduced quality of life, including the loss of muscle mass, increased fragility, risk of falls and hospitalisation, as well as a loss of independence [217]. It is not surprising that low vitamin D levels are linked with sarcopenia risk [218] and various metabolic diseases [219]. However, evidence is equivocal on the effectiveness of vitamin D supplementation for preventing or treating sarcopenia, partly due to study designs and intervention differences [220]. Interestingly, combining vitamin D with protein (especially sources rich in leucine) appears to confer more consistent positive outcomes in increasing muscle mass, strength and performance in sarcopenic older adults compared to placebo or standard practice [221]. A recent review supported the role of vitamin D deficiency in osteosarcopenic obesity development; however, no trial has assessed the efficacy of supplementation in this population [222]. Vitamin D supplementation has also been suggested for managing sarcopenia in heart failure patients by modulating inflammation, blood pressure and endothelial function [223], but more research is needed. It is important to note that interactions between certain drugs and vitamin D absorption or metabolism have been proposed, including treatments for obesity (e.g., lipase inhibitors) and CVD prevention (e.g., statins) [217]. Further investigation into these interactions is warranted to corroborate their potential impact on sarcopenic symptoms in older adults with CVD and MDs. Nevertheless, given the numerous essential roles of vitamin D, supplementation is recommended, particularly for older adults at risk of insufficient levels. To achieve a serum 25-hydroxyvitamin D level of approximately 75 nmol/L, the International Osteoporosis Foundation recommends a daily intake of 20–25 µg/day or 800–1000 IU/day for older adults [224].

4.4. The Gut Microbiota–Skeletal Muscle Axis: Implications for Sarcopenia, CVD and Obesity

Gut microbiota play a crucial role in maintaining health, influencing various physiological and metabolic processes including nutrient digestion and absorption, the production and regulation of short-chain fatty acids, inflammation and immune function and appetite and food intake [225,226]. Gut health has been associated with many clinical conditions and diseases including sarcopenia, obesity and CVD [225,227]. The gut–muscle axis, a relatively new concept, suggests that microbiota can protect against age-related muscle loss and dysfunction [228–230]. Differences in microbiota composition are observed between frail, sarcopenic patients and non-sarcopenic controls [231,232]. Gut microbiota dysbiosis, with reduced microbial diversity and beneficial bacteria, is more common in advanced age, similar to sarcopenia and CVD [233]. The health and composition of gut microbiota, which can impact age-related conditions, are influenced by various factors including genetics,

biological sex, ethnicity, environment, antibiotic use, physical activity, and diet [225]. To target the gut microbiota–skeletal muscle axis and improve these conditions, strategies such as increasing the intake of probiotics and prebiotic fibre have demonstrated positive effects on the gut microbiome in older adults [234]. Promising links have been observed between increased dietary intakes of probiotics and prebiotic dietary fibre intake and sarcopenia symptoms [226,228,235]. Most evidence in this area relies on rodent/animal models, with human studies mainly focusing on associations between gut health and muscle markers. To our knowledge, no randomized controlled trials have targeted the human microbiome of sarcopenic individuals, and more research is warranted.

5. Multidisciplinary Approaches

Interventions designed to manage sarcopenia, CVD and MDs are multi-faceted. It is well documented that physical activity (PA) interventions, particularly progressive, resistance training prescriptions, can have a positive impact on preventing the deterioration of both muscle mass and function in adults aged ≥ 60 years [236] and amongst people living with CVD [237]. The 2020 World Health Organization [238] and the United Kingdom's Chief Medical Officers' PA guidelines [239] have recently updated their recommendations to emphasise new understanding of the importance of muscle strengthening activities. Despite the robustness of the evidence, population adherence rates remain low [240], possibly due to lack of awareness of strength-based guidance for both clinical and non-clinical populations [241] as well as cognitive preferences and capabilities that suggest 'reluctance'. To address muscle loss, as highlighted in the previous section, nutrition interventions focused on addressing protein deficiencies have been shown to be beneficial [242]; however, other nutrition strategies focus on the consumption of vitamin D or the removal of alcohol and fatty acids from the diet [243]. The next subsection delves into some of the challenges older adults may encounter when trying to engage in both physical activity and nutrition interventions.

5.1. Challenges of Engaging in Interventions

Older populations attempting to engage in both PA and nutrition interventions for sarcopenia, CVD and MDs face a myriad of challenges. These challenges may include pain, fatigue, fear of movement and physical harm, lack of social support and lack of motivation among others [244,245]. Additionally, older adults often accept and believe that muscle degeneration is an inevitable part of the ageing process [246] and believe they are too old to learn and benefit from exercise [247]. However, challenging this belief through education on how muscle can be developed at any age through diet and exercise could enhance engagement in PA and protein intake. Another challenge comes from professional attitudes; in the phenomenon of 'compassionate ageism', programme staff view older adults as requiring protection from the high level of effort that can be associated with engaging in strength training [240]. Moreover, the desire to avoid vigorous exercise may also stem from a historical perspective of engaging in physical labour, leading to the notion of "going lighter as I get older". Interestingly, this misconception about avoiding vigorous intensity applies to both aerobic and strength training participation and is highlighted in national PA recommendations and guidelines for older adults [240].

5.2. What Are the Possible Ways Address These Challenges?

For interventions to be effective, it is pertinent that practitioners understand and work to overcome known barriers. One way this could be achieved is by modifying behaviour, a topic that has generated increasing attention in recent literature, particularly in relation to individuals with sarcopenia and/or CVD/MDs. Evidence of behavioural change has emerged from recent randomised controlled trials (e.g., [248,249]), systematic reviews (e.g., [250,251]), meta-analyses (e.g., [248,249,252,253]) and studies established to inform programme design and improvement (e.g., [254–256]). It is imperative that practitioners understand the underlying principles and mechanisms underpinning intervention design

for this population to bring about meaningful changes. When designing interventions, it is important to consider the challenges affecting daily behaviour; limited uptake and engagement may be more to do with the system(s) that support them as with the individual. A multifactor approach is needed. For example, this could involve supplementing individualised processes (e.g., accentuating motivation and capability), with social processes (e.g., involving copying others, conformity and cooperation) and structural factors (e.g., legislation and incentives) [257]. As such, approaches are needed that support both participants and those delivering the interventions. Ting-ru et al. [258] provided insight into the facilitators of PA for those living with sarcopenia and diabetes. The study revealed the motivational power of the perceived benefits of increased vitality, strength and appetite. Furthermore, this study highlighted the significance of recognising the limitations imposed by life circumstances when designing exercise routines. For instance, this could involve modifying the range of activities or adapting them to be done at home, using assistive devices (e.g., an umbrella for walking), to be active with friends, or using a wheelchair to get to a park and to plan routes where walking areas allow easy access and passage despite pre-existing and/or disease-specific limitations.

Van den Helder et al. [259] presented a recent case of an intervention that implemented client-centred behaviour modification to enhance physical performance and counteract the decline in physical function and sarcopenia. This intervention included exercise and protein counselling and resulted in improvements in muscle mass, strength, protein intake, gait strength and physical activity levels. Behaviour modification was based on the principles highlighted by the Medical Council Framework for behaviour change [260] and was personalised by using a mobile application [261]. This incorporated effective behaviour change techniques of goal setting, action planning and self-monitoring, as identified by the CALO-RE taxonomy [262]. Behaviour modification interventions are often based on recent theories and models such as the COM-B and dual-mode approaches to behaviour change [263]. These theories emphasise the importance of both self-regulation (e.g., goal setting) and automatic affective associations (e.g., promoting feelings of pleasure, well-being, connection and control) [264]. It is suggested that interventions underpinned by theory have better outcomes and higher adherence rates [265]. Therefore, when designing interventions, practitioners should strive to incorporate a theoretical foundation to support their approach, emphasising interventions that over-ride the barriers clients identify as being most influential.

Policy makers are increasingly turning to behavioural science for insights into how to improve both decisions and outcomes [266]. For example, a recent “mega” study found that offering small financial incentives, also known as micro incentives, could generate larger treatment and adherence effects and still attain the desired outcome [267]. Equally, experiencing the intrinsic reward of immediate joy and fun alongside evidence of personal progress provides a powerful mix of incentives for prolonging persistence [268] and one that could be considered for this area.

To achieve long-term adherence, incorporating technology is increasingly recommended; in mHealth and eHealth, for example, personalised apps for tablets have proven effective in promoting adherence to PA and diet interventions in older adults [259,269]. Furthermore, an mHealth randomised controlled trial used FitBit trackers to predict 12-month PA engagement and found that the best predictor of engagement was adherence in week one, which was achieved by 66.5% of the participants [270]. Notwithstanding a sample dominated by programme-ready, overweight–obese females (80%), replicating these findings would support reframing the powerful message of ‘every contact counts’ into ‘first week contacts count most’. For this reason, ensuring that individuals feel welcomed, included and valued [271] is critical in creating positive initial experiences within any programme. Moreover, older adults living independently with frailty are more likely to experience heightened social and or physical isolation [272]. Therefore, investing in interventions that can be remotely designed and delivered through technology could be advantageous. This approach supports those living independently, with frailty, who struggle independently

outside their own home, or have heightened anxiety of contact with people outside their home [273].

6. Conclusions and Future Directions

In conclusion, breaking the vicious cycle of sarcopenia in older adults with cardiovascular and metabolic diseases necessitates a multifaceted approach that encompasses exercise, nutrition and multidisciplinary interventions. The importance of incorporating combined training, comprehensive nutrition strategies and behavioural science integration to address sarcopenia in older adults with CVD and MDs has been highlighted in this review. These interventions are crucial in the prevention and management of sarcopenia and related conditions. Relevant stakeholders are strongly encouraged to implement these evidence-based strategies in their practice to improve patient outcomes (Figure 2). While our review provides a comprehensive summary of the available literature on this topic, incorporating perspectives from various disciplines, it is important to note that due to the scope of our literature search, some relevant studies may have been overlooked. This could potentially impact the comprehensiveness of our review and limit the generalizability of our findings. Future research should focus on high-quality randomized controlled trials to improve exercise and nutritional interventions while also examining the best ways to incorporate behavioural science into everyday practices for better initial adoption and for longer-term success of sarcopenia interventions. Further research is needed to investigate the unique challenges and barriers associated with different disease types, frailty, supervision and resources to facilitate systemic change and individual empowerment. Ultimately, a coordinated effort in these areas can improve health outcomes, well-being and quality of life in older adults with sarcopenia and coexisting cardiovascular and metabolic diseases.




Figure 2. Multidisciplinary approaches to address sarcopenia in older adults with cardiovascular and metabolic diseases. The figure was created with [BioRender.com](https://www.biorender.com) (accessed on 15 March 2023).

Author Contributions: Conceptualization, T.I., O.W., D.M., A.S.-K., L.D., M.A.B., L.S., A.J.P., J.H. and J.M. Writing and drafts of relevant sections T.I., O.W., D.M., L.A., P.F., G.L., A.S.-K., L.D., M.A.B., L.S., A.J.P., V.A., J.H. and J.M. Original draft preparation of main manuscript T.I. Project oversight T.I. Review and editing T.I., O.W., D.M., L.A., P.F., G.L., A.S.-K., L.D., M.A.B., L.S., A.J.P., V.A., J.H. and J.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Budreviciute, A.; Damiani, S.; Sabir, D.K.; Onder, K.; Schuller-Goetzburg, P.; Plakys, G.; Katileviciute, A.; Khoja, S.; Kodzius, R. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. *Front. Public Health* **2020**, *8*, 574111. [CrossRef] [PubMed]
- Gaziano, T.; Reddy, K.S.; Paccaud, F.; Horton, S.; Chaturvedi, V. Cardiovascular disease. In *Disease Control Priorities in Developing Countries*, 2nd ed.; The International Bank for Reconstruction and Development: Washington, DC, USA, 2006.
- Pradhan, A. Obesity, Metabolic Syndrome, and Type 2 Diabetes: Inflammatory Basis of Glucose Metabolic Disorders. *Nutr. Rev.* **2007**, *65*, S152–S156. [CrossRef] [PubMed]
- WHO. Cardiovascular Diseases. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (accessed on 6 January 2023).
- Timmis, A.; Townsend, N.; Gale, C.P.; Torbica, A.; Lettino, M.; Petersen, S.E.; Mossialos, E.A.; Maggioni, A.P.; Kazakiewicz, D.; May, H.T.; et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *Eur. Heart J.* **2020**, *41*, 12–85. [CrossRef] [PubMed]
- Rodgers, J.L.; Jones, J.; Bolleddu, S.I.; Vanthenapalli, S.; Rodgers, L.E.; Shah, K.; Karia, K.; Panguluri, S.K. Cardiovascular Risks Associated with Gender and Aging. *J. Cardiovasc. Dev. Dis.* **2019**, *6*, 19. [CrossRef] [PubMed]
- Huynh-Hohnbaum, A.-L.T.; Marshall, L.; Villa, V.M.; Lee, G. Self-Management of Heart Disease in Older Adults. *Home Health Care Serv. Q.* **2015**, *34*, 159–172. [CrossRef]
- Virani, S.S.; Alonso, A.; Aparicio, H.J.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics—2021 Update. *Circulation* **2021**, *143*, e254–e743. [CrossRef]
- Vellas, B.; Fielding, R.A.; Bens, C.; Bernabei, R.; Cawthon, P.M.; Cederholm, T.; Cruz-Jentoft, A.J.; Del Signore, S.; Donahue, S.; Morley, J.; et al. Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force. *J. Frailty Aging* **2018**, *7*, 2–9. [CrossRef]
- Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyere, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* **2019**, *48*, 16–31. [CrossRef]
- Beaudart, C.; Zaaria, M.; Pasleau, F.; Reginster, J.Y.; Bruyere, O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. *PLoS ONE* **2017**, *12*, e0169548. [CrossRef]
- Cruz-Jentoft, A.J.; Landi, F.; Topinkova, E.; Michel, J.P. Understanding sarcopenia as a geriatric syndrome. *Curr. Opin. Clin. Nutr. Metab. Care* **2010**, *13*, 1–7. [CrossRef]
- Li, Z.; Tong, X.; Ma, Y.; Bao, T.; Yue, J. Prevalence of depression in patients with sarcopenia and correlation between the two diseases: Systematic review and meta-analysis. *J. Cachexia Sarcopenia Muscle* **2022**, *13*, 128–144. [CrossRef] [PubMed]
- Ali, S.; Garcia, J.M. Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options—A mini-review. *Gerontology* **2014**, *60*, 294–305. [CrossRef] [PubMed]
- Walston, J.D. Sarcopenia in older adults. *Curr. Opin. Rheumatol.* **2012**, *24*, 623–627. [CrossRef] [PubMed]
- Borba, V.Z.C.; Costa, T.L.; Moreira, C.A.; Boguszewski, C.L. Mechanisms of endocrine disease: Sarcopenia in endocrine and non-endocrine disorders. *Eur. J. Endocrinol.* **2019**, *180*, R185–R199. [CrossRef] [PubMed]
- Ispoglou, T.; Witard, O.C.; Duckworth, L.C.; Lees, M.J. The efficacy of essential amino acid supplementation for augmenting dietary protein intake in older adults: Implications for skeletal muscle mass, strength and function. *Proc. Nutr. Soc.* **2021**, *80*, 230–242. [CrossRef] [PubMed]
- Gao, K.; Cao, L.-F.; Ma, W.-Z.; Gao, Y.-J.; Luo, M.-S.; Zhu, J.; Li, T.; Zhou, D. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: Findings from the China health and retirement longitudinal study. *eClinicalMedicine* **2022**, *44*, 101264. [CrossRef]
- Rivera-Torres, S.; Fahey, T.D.; Rivera, M.A. Adherence to Exercise Programs in Older Adults: Informative Report. *Gerontol. Geriatr. Med.* **2019**, *5*, 2333721418823604. [CrossRef]

20. Bian, W.; Wang, Z.; Wan, J.; Zhang, F.; Wu, X.; Li, X.; Luo, Y. Exploring challenges to nutrition intervention adherence using COM-B model among patients with wet age-related macular degeneration: A qualitative study. *BMJ Open* **2022**, *12*, e064892. [[CrossRef](#)]
21. Moore, L.; Britten, N.; Lydahl, D.; Naldemirci, Ö.; Elam, M.; Wolf, A. Barriers and facilitators to the implementation of person-centred care in different healthcare contexts. *Scand. J. Caring Sci.* **2017**, *31*, 662–673. [[CrossRef](#)]
22. Coulter, A.; Oldham, J. Person-centred care: What is it and how do we get there? *Future Hosp. J.* **2016**, *3*, 114–116. [[CrossRef](#)]
23. Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.; Himmelfarb, C.D.; Khera, A.; Lloyd-Jones, D.; McEvoy, J.W.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* **2019**, *74*, e177–e232. [[CrossRef](#)] [[PubMed](#)]
24. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Eur. Heart J.* **2020**, *41*, 111–188. [[CrossRef](#)] [[PubMed](#)]
25. Calvani, R.; Joseph, A.M.; Adhihetty, P.J.; Micheli, A.; Bossola, M.; Leeuwenburgh, C.; Bernabei, R.; Marzetti, E. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. *Biol. Chem.* **2013**, *394*, 393–414. [[CrossRef](#)] [[PubMed](#)]
26. Picca, A.; Calvani, R.; Bossola, M.; Allocca, E.; Menghi, A.; Pesce, V.; Lezza, A.M.S.; Bernabei, R.; Landi, F.; Marzetti, E. Update on mitochondria and muscle aging: All wrong roads lead to sarcopenia. *Biol. Chem.* **2018**, *399*, 421–436. [[CrossRef](#)]
27. Conley, K.E.; Jubrias, S.A.; Esselman, P.C. Oxidative capacity and ageing in human muscle. *J. Physiol.* **2000**, *526 Pt 1*, 203–210. [[CrossRef](#)]
28. Crane, J.D.; Devries, M.C.; Safdar, A.; Hamadeh, M.J.; Tarnopolsky, M.A. The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2010**, *65*, 119–128. [[CrossRef](#)]
29. Örländer, J.; Kiessling, K.-H.; Larsson, L.; Karlsson, J.; Aniansson, A. Skeletal muscle metabolism and ultrastructure in relation to age in sedentary men. *Acta Physiol. Scand.* **1978**, *104*, 249–261. [[CrossRef](#)]
30. Broskey, N.T.; Greggio, C.; Boss, A.; Boutant, M.; Dwyer, A.; Schlueter, L.; Hans, D.; Gremion, G.; Kreis, R.; Boesch, C.; et al. Skeletal muscle mitochondria in the elderly: Effects of physical fitness and exercise training. *J. Clin. Endocrinol. Metab.* **2014**, *99*, 1852–1861. [[CrossRef](#)]
31. Boffoli, D.; Scacco, S.C.; Vergari, R.; Solarino, G.; Santacroce, G.; Papa, S. Decline with age of the respiratory chain activity in human skeletal muscle. *Biochim. Biophys. Acta* **1994**, *1226*, 73–82. [[CrossRef](#)]
32. Coggan, A.R.; Spina, R.J.; King, D.S.; Rogers, M.A.; Brown, M.; Nemeth, P.M.; Holloszy, J.O. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. *J. Gerontol.* **1992**, *47*, B71–B76. [[CrossRef](#)]
33. Tonkonogi, M.; Fernstrom, M.; Walsh, B.; Ji, L.L.; Rooyackers, O.; Hammarqvist, F.; Wernerman, J.; Sahlin, K. Reduced oxidative power but unchanged antioxidative capacity in skeletal muscle from aged humans. *Pflugers Arch.* **2003**, *446*, 261–269. [[CrossRef](#)] [[PubMed](#)]
34. Petersen, K.F.; Befroy, D.; Dufour, S.; Dziura, J.; Ariyan, C.; Rothman, D.L.; DiPietro, L.; Cline, G.W.; Shulman, G.I. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. *Science* **2003**, *300*, 1140–1142. [[CrossRef](#)] [[PubMed](#)]
35. Amara, C.E.; Shankland, E.G.; Jubrias, S.A.; Marcinek, D.J.; Kushmerick, M.J.; Conley, K.E. Mild mitochondrial uncoupling impacts cellular aging in human muscles in vivo. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 1057–1062. [[CrossRef](#)] [[PubMed](#)]
36. Migliavacca, E.; Tay, S.K.H.; Patel, H.P.; Sonntag, T.; Civiletto, G.; McFarlane, C.; Forrester, T.; Barton, S.J.; Leow, M.K.; Antoun, E.; et al. Mitochondrial oxidative capacity and NAD(+) biosynthesis are reduced in human sarcopenia across ethnicities. *Nat. Commun.* **2019**, *10*, 5808. [[CrossRef](#)]
37. Su, J.; Ekman, C.; Oskolkov, N.; Lahti, L.; Strom, K.; Brazma, A.; Groop, L.; Rung, J.; Hansson, O. A novel atlas of gene expression in human skeletal muscle reveals molecular changes associated with aging. *Skelet. Muscle* **2015**, *5*, 35. [[CrossRef](#)]
38. Rooyackers, O.E.; Kersten, A.H.; Wagenmakers, A.J. Mitochondrial protein content and in vivo synthesis rates in skeletal muscle from critically ill rats. *Clin. Sci.* **1996**, *91*, 475–481. [[CrossRef](#)]
39. Kelley, D.E.; He, J.; Menshikova, E.V.; Ritov, V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. *Diabetes* **2002**, *51*, 2944–2950. [[CrossRef](#)]
40. Ritov, V.B.; Menshikova, E.V.; He, J.; Ferrell, R.E.; Goodpaster, B.H.; Kelley, D.E. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. *Diabetes* **2005**, *54*, 8–14. [[CrossRef](#)]
41. Chomentowski, P.; Coen, P.M.; Radikova, Z.; Goodpaster, B.H.; Toledo, F.G. Skeletal muscle mitochondria in insulin resistance: Differences in intermyofibrillar versus subsarcolemmal subpopulations and relationship to metabolic flexibility. *J. Clin. Endocrinol. Metab.* **2011**, *96*, 494–503. [[CrossRef](#)]
42. Schrauwen-Hinderling, V.B.; Kooi, M.E.; Hesselink, M.K.; Jensen, J.A.; Backes, W.H.; van Echteld, C.J.; van Engelshoven, J.M.; Mensink, M.; Schrauwen, P. Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. *Diabetologia* **2007**, *50*, 113–120. [[CrossRef](#)]
43. Phielix, E.; Schrauwen-Hinderling, V.B.; Mensink, M.; Lenaers, E.; Meex, R.; Hoeks, J.; Kooi, M.E.; Moonen-Kornips, E.; Sels, J.P.; Hesselink, M.K.; et al. Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. *Diabetes* **2008**, *57*, 2943–2949. [[CrossRef](#)] [[PubMed](#)]

44. Grevendonk, L.; Connell, N.J.; McCrum, C.; Fealy, C.E.; Bilet, L.; Bruls, Y.M.H.; Mevenkamp, J.; Schrauwen-Hinderling, V.B.; Jörgensen, J.A.; Moonen-Kornips, E.; et al. Impact of aging and exercise on skeletal muscle mitochondrial capacity, energy metabolism, and physical function. *Nat. Commun.* **2021**, *12*, 4773. [[CrossRef](#)] [[PubMed](#)]
45. Nielsen, J.; Mogensen, M.; Vind, B.F.; Sahlin, K.; Hojlund, K.; Schroder, H.D.; Ortenblad, N. Increased subsarcolemmal lipids in type 2 diabetes: Effect of training on localization of lipids, mitochondria, and glycogen in sedentary human skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* **2010**, *298*, E706–E713. [[CrossRef](#)] [[PubMed](#)]
46. Larsen, S.; Nielsen, J.; Hansen, C.N.; Nielsen, L.B.; Wibrand, F.; Stride, N.; Schroder, H.D.; Boushel, R.; Helge, J.W.; Dela, F.; et al. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. *J. Physiol.* **2012**, *590*, 3349–3360. [[CrossRef](#)]
47. Mogensen, M.; Sahlin, K.; Fernstrom, M.; Glinborg, D.; Vind, B.F.; Beck-Nielsen, H.; Hojlund, K. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. *Diabetes* **2007**, *56*, 1592–1599. [[CrossRef](#)]
48. Boushel, R.; Gnaiger, E.; Schjerling, P.; Skovbro, M.; Kraunsoe, R.; Dela, F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. *Diabetologia* **2007**, *50*, 790–796. [[CrossRef](#)]
49. St-Jean-Pelletier, F.; Pion, C.H.; Leduc-Gaudet, J.P.; Sgaroto, N.; Zovile, I.; Barbat-Artigas, S.; Reynaud, O.; Alkaterji, F.; Lemieux, F.C.; Grenon, A.; et al. The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 213–228. [[CrossRef](#)]
50. Genders, A.J.; Holloway, G.P.; Bishop, D.J. Are Alterations in Skeletal Muscle Mitochondria a Cause or Consequence of Insulin Resistance? *Int. J. Mol. Sci.* **2020**, *21*, 6948. [[CrossRef](#)]
51. de Almeida, M.E.; Nielsen, J.; Petersen, M.H.; Wentorf, E.K.; Pedersen, N.B.; Jensen, K.; Hojlund, K.; Ortenblad, N. Altered intramuscular network of lipid droplets and mitochondria in type 2 diabetes. *Am. J. Physiol.-Cell Physiol.* **2023**, *324*, C39–C57. [[CrossRef](#)]
52. Gemmink, A.; Daemen, S.; Kuijpers, H.J.H.; Schaart, G.; Duimel, H.; Lopez-Iglesias, C.; van Zandvoort, M.; Knoop, K.; Hesselink, M.K.C. Super-resolution microscopy localizes perilipin 5 at lipid droplet-mitochondria interaction sites and at lipid droplets juxtaposing to perilipin 2. *Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids* **2018**, *1863*, 1423–1432. [[CrossRef](#)]
53. Daemen, S.; Gemmink, A.; Brouwers, B.; Meex, R.C.R.; Huntjens, P.R.; Schaart, G.; Moonen-Kornips, E.; Jorgensen, J.; Hoeks, J.; Schrauwen, P.; et al. Distinct lipid droplet characteristics and distribution unmask the apparent contradiction of the athlete’s paradox. *Mol. Metab.* **2018**, *17*, 71–81. [[CrossRef](#)]
54. Nielsen, J.; Christensen, A.E.; Nellemann, B.; Christensen, B. Lipid droplet size and location in human skeletal muscle fibers are associated with insulin sensitivity. *Am. J. Physiol. Endocrinol. Metab.* **2017**, *313*, E721–E730. [[CrossRef](#)]
55. Aas, V.; Thoresen, G.H.; Rustan, A.C.; Lund, J. Substrate oxidation in primary human skeletal muscle cells is influenced by donor age. *Cell Tissue Res.* **2020**, *382*, 599–608. [[CrossRef](#)]
56. Levadoux, E.; Morio, B.; Montaurier, C.; Puissant, V.; Boirie, Y.; Fellmann, N.; Picard, B.; Rousset, P.; Beaufriere, B.; Ritz, P. Reduced whole-body fat oxidation in women and in the elderly. *Int. J. Obes. Relat. Metab. Disord.* **2001**, *25*, 39–44. [[CrossRef](#)]
57. Solomon, T.P.; Marchetti, C.M.; Krishnan, R.K.; Gonzalez, F.; Kirwan, J.P. Effects of aging on basal fat oxidation in obese humans. *Metabolism* **2008**, *57*, 1141–1147. [[CrossRef](#)]
58. Sial, S.; Coggan, A.R.; Carroll, R.; Goodwin, J.; Klein, S. Fat and carbohydrate metabolism during exercise in elderly and young subjects. *Am. J. Physiol.* **1996**, *271*, E983–E989. [[CrossRef](#)] [[PubMed](#)]
59. Kelley, D.E.; Goodpaster, B.; Wing, R.R.; Simoneau, J.A. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. *Am. J. Physiol.* **1999**, *277*, E1130–E1141. [[CrossRef](#)] [[PubMed](#)]
60. Galgani, J.E.; Heilbronn, L.K.; Azuma, K.; Kelley, D.E.; Albu, J.B.; Pi-Sunyer, X.; Smith, S.R.; Ravussin, E.; Look, A.A.R.G. Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate. *Diabetes* **2008**, *57*, 841–845. [[CrossRef](#)] [[PubMed](#)]
61. Goodpaster, B.H.; Wolfe, R.R.; Kelley, D.E. Effects of obesity on substrate utilization during exercise. *Obes. Res.* **2002**, *10*, 575–584. [[CrossRef](#)]
62. Prior, S.J.; Ryan, A.S.; Stevenson, T.G.; Goldberg, A.P. Metabolic inflexibility during submaximal aerobic exercise is associated with glucose intolerance in obese older adults. *Obesity* **2014**, *22*, 451–457. [[CrossRef](#)] [[PubMed](#)]
63. Smith, R.L.; Soeters, M.R.; Wust, R.C.I.; Houtkooper, R.H. Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease. *Endocr. Rev.* **2018**, *39*, 489–517. [[CrossRef](#)] [[PubMed](#)]
64. Tsilingiris, D.; Tzeravini, E.; Koliaki, C.; Dalamaga, M.; Kokkinos, A. The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: An Updated Overview. *Curr. Obes. Rep.* **2021**, *10*, 191–213. [[CrossRef](#)] [[PubMed](#)]
65. Goodpaster, B.H.; Sparks, L.M. Metabolic Flexibility in Health and Disease. *Cell Metab.* **2017**, *25*, 1027–1036. [[CrossRef](#)] [[PubMed](#)]
66. Sergi, D.; Naumovski, N.; Heilbronn, L.K.; Abeywardena, M.; O’Callaghan, N.; Lionetti, L.; Luscombe-Marsh, N. Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet. *Front. Physiol.* **2019**, *10*, 532. [[CrossRef](#)] [[PubMed](#)]
67. Stout, M.B.; Justice, J.N.; Nicklas, B.J.; Kirkland, J.L. Physiological Aging: Links Among Adipose Tissue Dysfunction, Diabetes, and Frailty. *Physiology* **2017**, *32*, 9–19. [[CrossRef](#)]
68. Tchernof, A.; Després, J.P. Pathophysiology of human visceral obesity: An update. *Physiol. Rev.* **2013**, *93*, 359–404. [[CrossRef](#)]

69. Karlsson, T.; Rask-Andersen, M.; Pan, G.; Höglund, J.; Wadelius, C.; Ek, W.E.; Johansson, Å. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. *Nat. Med.* **2019**, *25*, 1390–1395. [[CrossRef](#)]
70. Wajchenberg, B.L.; Lé, B.; Wajchenberg, O. Subcutaneous and Visceral Adipose Tissue. *Endocr. Rev.* **2000**, *21*, 697–738. [[CrossRef](#)]
71. Klop, B.; Elte, J.W.F.; Cabezas, M.C. Dyslipidemia in Obesity: Mechanisms and Potential Targets. *Nutrients* **2013**, *5*, 1218–1240. [[CrossRef](#)]
72. Ivanova, E.A.; Myasoedova, V.A.; Melnichenko, A.A.; Grechko, A.V.; Orekhov, A.N. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. *Oxidative Med. Cell. Longev.* **2017**, *2017*, 1273042. [[CrossRef](#)]
73. Diffenderfer, M.R.; Schaefer, E.J. The composition and metabolism of large and small LDL. *Curr. Opin. Lipidol.* **2014**, *25*, 221–226. [[CrossRef](#)] [[PubMed](#)]
74. Hoogeveen, R.C.; Gaubatz, J.W.; Sun, W.; Dodge, R.C.; Crosby, J.R.; Jiang, J.; Couper, D.; Virani, S.S.; Kathiresan, S.; Boerwinkle, E.; et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 1069–1077. [[CrossRef](#)] [[PubMed](#)]
75. Fan, J.; Liu, Y.; Yin, S.; Chen, N.; Bai, X.; Ke, Q.; Shen, J.; Xia, M. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. *Nutr. Metab.* **2019**, *16*, 7. [[CrossRef](#)] [[PubMed](#)]
76. Di Angelantonio, E.; Sarwar, N.; Perry, P.; Al, E. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. *JAMA* **2009**, *302*, 1993–2000. [[CrossRef](#)] [[PubMed](#)]
77. Sharrett, A.R.; Ballantyne, C.M.; Coady, S.A.; Heiss, G.; Sorlie, P.D.; Catellier, D.; Patsch, W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* **2001**, *104*, 1108–1113. [[CrossRef](#)] [[PubMed](#)]
78. Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* **2017**, *38*, 2459–2472. [[CrossRef](#)]
79. Otvos, J.D.; Mora, S.; Shalurova, I.; Greenland, P.; MacKey, R.H.; Goff, D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. *J. Clin. Lipidol.* **2011**, *5*, 105–113. [[CrossRef](#)]
80. Sniderman, A.D.; Thanassoulis, G.; Glavinovic, T.; Navar, A.M.; Pencina, M.; Catapano, A.; Ference, B.A. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. *JAMA Cardiol.* **2019**, *4*, 1287–1295. [[CrossRef](#)]
81. Freiberg, J.J.; Tybjaerg-Hansen, A.; Jensen, J.S.; Nordestgaard, B.G. Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population. *JAMA* **2008**, *300*, 2142. [[CrossRef](#)]
82. Nordestgaard, B.G.; Benn, M.; Schnohr, P.; Tybjaerg-Hansen, A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *J. Am. Med. Assoc.* **2007**, *298*, 299–308. [[CrossRef](#)]
83. Katzmann, J.L.; Laufs, U. New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. *Curr. Cardiol. Rep.* **2019**, *21*, 69. [[CrossRef](#)] [[PubMed](#)]
84. Riaz, H.; Khan, S.U.; Rahman, H.; Shah, N.P.; Kaluski, E.; Lincoff, A.M.; Nissen, S.E. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. *Eur. J. Prev. Cardiol.* **2019**, *26*, 533–543. [[CrossRef](#)] [[PubMed](#)]
85. Santos-Gallego, C.G.; Torres, F.; Badimón, J.J.; Wu, M.Y.; Li, C.J.; Hou, M.F.; Chu, P.Y.; Kuipers, H.; Wijnen, J.A.G.; Hartgens, F.; et al. The beneficial effects of HDL-C on atherosclerosis: Rationale and clinical results. *Clin. Lipidol.* **2011**, *6*, 181–208. [[CrossRef](#)]
86. Fuster, V.; Moreno, P.R.; Fayad, Z.A.; Corti, R.; Badimon, J.J. Atherothrombosis and high-risk plaque: Part I: Evolving concepts. *J. Am. Coll. Cardiol.* **2005**, *46*, 937–954. [[CrossRef](#)]
87. Khera, A.V.; Cuchel, M.; de la Llera-Moya, M.; Rodrigues, A.; Burke, M.F.; Jafri, K.; French, B.C.; Phillips, J.A.; Mucksavage, M.L.; Wilensky, R.L.; et al. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. *N. Engl. J. Med.* **2011**, *364*, 127–135. [[CrossRef](#)]
88. Qiu, C.; Zhao, X.; Zhou, Q.; Zhang, Z. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: A systematic review and meta-analysis. *Lipids Health Dis.* **2017**, *16*, 212. [[CrossRef](#)]
89. Rader, D.J.; Hovingh, G.K. HDL and cardiovascular disease. *Lancet* **2014**, *384*, 618–625. [[CrossRef](#)]
90. Ruiz-Ramie, J.J.; Barber, J.L.; Sarzynski, M.A. Effects of exercise on HDL functionality. *Curr. Opin. Lipidol.* **2019**, *30*, 16–23. [[CrossRef](#)]
91. Nordestgaard, B.G.; Varbo, A. Triglycerides and cardiovascular disease. *Lancet* **2014**, *384*, 626–635. [[CrossRef](#)]
92. Duran, E.K.; Aday, A.W.; Cook, N.R.; Buring, J.E.; Ridker, P.M.; Pradhan, A.D. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. *J. Am. Coll. Cardiol.* **2020**, *75*, 2122–2135. [[CrossRef](#)]
93. Kawai, T.; Autieri, M.V.; Scalia, R. Adipose tissue inflammation and metabolic dysfunction in obesity. *Am. J. Physiol.-Cell Physiol.* **2021**, *320*, C375–C391. [[CrossRef](#)]
94. Park, H.S.; Park, J.Y.; Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF- α and IL-6. *Diabetes Res. Clin. Pract.* **2005**, *69*, 29–35. [[CrossRef](#)] [[PubMed](#)]
95. Kang, Y.E.; Kim, J.M.; Joung, K.H.; Lee, J.H.; You, B.R.; Choi, M.J.; Ryu, M.J.; Ko, Y.B.; Lee, M.A.; Lee, J.; et al. The roles of adipokines, proinflammatory cytokines, and adipose tissue macrophages in obesity-associated insulin resistance in modest obesity and early metabolic dysfunction. *PLoS ONE* **2016**, *11*, e0154003. [[CrossRef](#)] [[PubMed](#)]

96. Zhang, X.-Y.; Su, C.; Cao, Z.; Xu, S.-Y.; Xia, W.-H.; Xie, W.-L.; Chen, L.; Yu, B.-B.; Zhang, B.; Wang, Y. CXCR7 upregulation is required for early endothelial progenitor cell-mediated endothelial repair in patients with hypertension. *Hypertension* **2014**, *63*, 383–389. [[CrossRef](#)]
97. Petrie, J.R.; Guzik, T.J.; Touyz, R.M. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. *Can. J. Cardiol.* **2018**, *34*, 575–584. [[CrossRef](#)] [[PubMed](#)]
98. Timmerman, K.L.; Lee, J.L.; Dreyer, H.C.; Dhanani, S.; Glynn, E.L.; Fry, C.S.; Drummond, M.J.; Sheffield-Moore, M.; Rasmussen, B.B.; Volpi, E. Insulin stimulates human skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of rapamycin complex 1 signaling. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 3848–3857. [[CrossRef](#)] [[PubMed](#)]
99. Tokarz, V.L.; MacDonald, P.E.; Klip, A. The cell biology of systemic insulin function. *J. Cell Biol.* **2018**, *217*, 2273–2289. [[CrossRef](#)] [[PubMed](#)]
100. Muniyappa, R.; Sowers, J.R. Role of insulin resistance in endothelial dysfunction. *Rev. Endocr. Metab. Disord.* **2013**, *14*, 5–12. [[CrossRef](#)]
101. Touyz, R.M.; Li, H.; Delles, C. ACE2 the Janus-faced protein—from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. *Clin. Sci.* **2020**, *134*, 747–750. [[CrossRef](#)]
102. Barvitenko, N.; Skverchinskaya, E.; Lawen, A.; Matteucci, E.; Saldanha, C.; Uras, G.; Manca, A.; Aslam, M.; Pantaleo, A. Pleiotropic and potentially beneficial effects of reactive oxygen species on the intracellular signaling pathways in endothelial cells. *Antioxidants* **2021**, *10*, 904. [[CrossRef](#)]
103. Boucher, J.; Kleinriders, A.; Kahn, C.R. Insulin Receptor Signaling in Normal and Insulin-Resistant States. *Cold Spring Harb. Perspect. Biol.* **2014**, *6*, a009191. [[CrossRef](#)]
104. Petersen, M.C.; Shulman, G.I. Mechanisms of insulin action and insulin resistance. *Physiol. Rev.* **2018**, *98*, 2133–2223. [[CrossRef](#)] [[PubMed](#)]
105. Arpón, A.; Milagro, F.I.; Santos, J.L.; García-Granero, M.; Riezu-Boj, J.I.; Martínez, J.A. Interaction among sex, aging, and epigenetic processes concerning visceral fat, insulin resistance, and dyslipidaemia. *Front. Endocrinol.* **2019**, *10*, 496. [[CrossRef](#)] [[PubMed](#)]
106. Shorakae, S.; Ranasinha, S.; Abell, S.; Lambert, G.; Lambert, E.; de Courten, B.; Teede, H. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. *Clin. Endocrinol.* **2018**, *89*, 628–633. [[CrossRef](#)] [[PubMed](#)]
107. Ormazabal, V.; Nair, S.; Elfeky, O.; Aguayo, C.; Salomon, C.; Zuñiga, F.A. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc. Diabetol.* **2018**, *17*, 122. [[CrossRef](#)]
108. Manning, B.D.; Toker, A. AKT/PKB Signaling: Navigating the Network. *Cell* **2017**, *169*, 381–405. [[CrossRef](#)]
109. Li, D.T.; Habtemichael, E.N.; Julca, O.; Sales, C.I.; Westergaard, X.O.; DeVries, S.G.; Ruiz, D.; Sayal, B.; Bogan, J.S. GLUT4 storage vesicles: Specialized organelles for regulated trafficking. *Yale J. Biol. Med.* **2019**, *92*, 453–470.
110. DeFronzo, R.A.; Tobin, J.D.; Andres, R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. *Am. J. Physiol.-Endocrinol. Metab.* **1979**, *237*, E214. [[CrossRef](#)]
111. Wilcox, G. Insulin and insulin resistance. *Clin. Biochem. Rev.* **2005**, *26*, 19–39. [[CrossRef](#)]
112. Turner, N.; Cooney, G.J.; Kraegen, E.W.; Bruce, C.R. Fatty acid metabolism, energy expenditure and insulin resistance in muscle. *J. Endocrinol.* **2014**, *220*, T61–T79. [[CrossRef](#)]
113. Heeren, J.; Scheja, L. Metabolic-associated fatty liver disease and lipoprotein metabolism. *Mol. Metab.* **2021**, *50*, 101238. [[CrossRef](#)] [[PubMed](#)]
114. Goldin, A.; Beckman, J.A.; Schmidt, A.M.; Creager, M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. *Circulation* **2006**, *114*, 597–605. [[CrossRef](#)] [[PubMed](#)]
115. Anderson, E.J.; Lustig, M.E.; Boyle, K.E.; Woodlief, T.L.; Kane, D.A.; Lin, C.T.; Price, J.W., 3rd; Kang, L.; Rabinovitch, P.S.; Szeto, H.H.; et al. Mitochondrial H₂O₂ emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. *J. Clin. Investig.* **2009**, *119*, 573–581. [[CrossRef](#)] [[PubMed](#)]
116. Foreman, N.A.; Hesse, A.S.; Ji, L.L. Redox Signaling and Sarcopenia: Searching for the Primary Suspect. *Int. J. Mol. Sci.* **2021**, *22*, 9045. [[CrossRef](#)]
117. Di Meo, S.; Iossa, S.; Venditti, P. Skeletal muscle insulin resistance: Role of mitochondria and other ROS sources. *J. Endocrinol.* **2017**, *233*, R15–R42. [[CrossRef](#)]
118. Harper, C.; Gopalan, V.; Goh, J. Exercise rescues mitochondrial coupling in aged skeletal muscle: A comparison of different modalities in preventing sarcopenia. *J. Transl. Med.* **2021**, *19*, 71. [[CrossRef](#)]
119. Zorov, D.B.; Juhaszova, M.; Sollott, S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol. Rev.* **2014**, *94*, 909–950. [[CrossRef](#)]
120. Romanello, V.; Sandri, M. Mitochondrial biogenesis and fragmentation as regulators of muscle protein degradation. *Curr. Hypertens. Rep.* **2010**, *12*, 433–439. [[CrossRef](#)]
121. Ji, L.L.; Kang, C. Role of PGC-1 α in sarcopenia: Etiology and potential intervention—A mini-review. *Gerontology* **2015**, *61*, 139–148. [[CrossRef](#)] [[PubMed](#)]
122. Distefano, G.; Goodpaster, B.H. Effects of Exercise and Aging on Skeletal Muscle. *Cold Spring Harb. Perspect. Med.* **2018**, *8*, a029785. [[CrossRef](#)]

123. Joannis, S.; Ashcroft, S.; Wilkinson, D.J.; Pollock, R.D.; O'Brien, K.A.; Phillips, B.E.; Smith, K.; Lazarus, N.R.; Harridge, S.D.R.; Atherton, P.J.; et al. High Levels of Physical Activity in Later Life Are Associated With Enhanced Markers of Mitochondrial Metabolism. *J. Gerontol. Biol. Sci. Med. Sci.* **2020**, *75*, 1481–1487. [[CrossRef](#)] [[PubMed](#)]
124. Tezze, C.; Romanello, V.; Desbats, M.A.; Fadini, G.P.; Albiero, M.; Favaro, G.; Ciciliot, S.; Soriano, M.E.; Morbidoni, V.; Cerqua, C.; et al. Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass, Metabolic Homeostasis, Systemic Inflammation, and Epithelial Senescence. *Cell Metab.* **2017**, *25*, 1374–1389. [[CrossRef](#)] [[PubMed](#)]
125. Mootha, V.K.; Lindgren, C.M.; Eriksson, K.F.; Subramanian, A.; Sihag, S.; Lehar, J.; Puigserver, P.; Carlsson, E.; Ridderstrale, M.; Laurila, E.; et al. PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **2003**, *34*, 267–273. [[CrossRef](#)] [[PubMed](#)]
126. Houzelle, A.; Jorgensen, J.A.; Schaart, G.; Daemen, S.; van Polanen, N.; Fealy, C.E.; Hesselink, M.K.C.; Schrauwen, P.; Hoeks, J. Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity. *Diabetologia* **2021**, *64*, 424–436. [[CrossRef](#)] [[PubMed](#)]
127. Fiatarone, M.A.; Marks, E.C.; Ryan, N.D.; Meredith, C.N.; Lipsitz, L.A.; Evans, W.J. High-intensity strength training in nonagenarians. Effects on skeletal muscle. *JAMA* **1990**, *263*, 3029–3034. [[CrossRef](#)]
128. Short, K.R.; Vittone, J.L.; Bigelow, M.L.; Proctor, D.N.; Rizza, R.A.; Coenen-Schimke, J.M.; Nair, K.S. Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. *Diabetes* **2003**, *52*, 1888–1896. [[CrossRef](#)]
129. Sial, S.; Coggan, A.R.; Hickner, R.C.; Klein, S. Training-induced alterations in fat and carbohydrate metabolism during exercise in elderly subjects. *Am. J. Physiol.* **1998**, *274*, E785–E790. [[CrossRef](#)]
130. Vissers, D.; Hens, W.; Taeymans, J.; Baeyens, J.P.; Poortmans, J.; Van Gaal, L. The effect of exercise on visceral adipose tissue in overweight adults: A systematic review and meta-analysis. *PLoS ONE* **2013**, *8*, e56415. [[CrossRef](#)]
131. Gonzalo-Encabo, P.; Maldonado, G.; Valades, D.; Ferragut, C.; Perez-Lopez, A. The Role of Exercise Training on Low-Grade Systemic Inflammation in Adults with Overweight and Obesity: A Systematic Review. *Int. J. Environ. Res. Public Health* **2021**, *18*, 13258. [[CrossRef](#)]
132. Cox, J.H.; Cortright, R.N.; Dohm, G.L.; Houmard, J.A. Effect of aging on response to exercise training in humans: Skeletal muscle GLUT-4 and insulin sensitivity. *J. Appl. Physiol.* **1999**, *86*, 2019–2025. [[CrossRef](#)]
133. Dent, E.; Morley, J.E.; Cruz-Jentoft, A.J.; Arai, H.; Kritchevsky, S.B.; Guralnik, J.; Bauer, J.M.; Pahor, M.; Clark, B.C.; Cesari, M.; et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. *J. Nutr. Health Aging* **2018**, *22*, 1148–1161. [[CrossRef](#)] [[PubMed](#)]
134. Hurst, C.; Robinson, S.M.; Witham, M.D.; Dodds, R.M.; Granic, A.; Buckland, C.; De Biase, S.; Finnegan, S.; Rochester, L.; Skelton, D.A.; et al. Resistance exercise as a treatment for sarcopenia: Prescription and delivery. *Age Ageing* **2022**, *51*, afac003. [[CrossRef](#)] [[PubMed](#)]
135. Bowen, T.S.; Schuler, G.; Adams, V. Skeletal muscle wasting in cachexia and sarcopenia: Molecular pathophysiology and impact of exercise training. *J. Cachexia Sarcopenia Muscle* **2015**, *6*, 197–207. [[CrossRef](#)] [[PubMed](#)]
136. He, N.; Zhang, Y.; Zhang, L.; Zhang, S.; Ye, H. Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview. *Front. Cardiovasc. Med.* **2021**, *8*, 743710. [[CrossRef](#)]
137. Argyropoulou, D.; Geladas, N.D.; Nomikos, T.; Paschalis, V. Exercise and Nutrition Strategies for Combating Sarcopenia and Type 2 Diabetes Mellitus in Older Adults. *J. Funct. Morphol. Kinesiol.* **2022**, *7*, 48. [[CrossRef](#)]
138. Bekfani, T.; Pellicori, P.; Morris, D.A.; Ebner, N.; Valentova, M.; Steinbeck, L.; Wachter, R.; Elsner, S.; Sliziuk, V.; Schefold, J.C.; et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. *Int. J. Cardiol.* **2016**, *222*, 41–46. [[CrossRef](#)]
139. Bemben, A.D.; Feters, L.N.; Bemben, G.M.; Nabavi, N.; Koh, T.E. Musculoskeletal responses to high- and low-intensity resistance training in early postmenopausal women. *Phys. Fit. Perform.* **2000**, *32*, 1949–1957. [[CrossRef](#)]
140. Aagaard, P.; Suetta, C.; Caserotti, P.; Magnusson, S.P.; Kjaer, M. Role of the nervous system in sarcopenia and muscle atrophy with aging: Strength training as a countermeasure. *Scand. J. Med. Sci. Sports* **2010**, *20*, 49–64. [[CrossRef](#)]
141. Forbes, S.C.; Little, J.P.; Candow, D.G. Exercise and nutritional interventions for improving aging muscle health. *Endocrine* **2012**, *42*, 29–38. [[CrossRef](#)]
142. Tan, S.; Li, W.; Wang, J. Effects of six months of combined aerobic and resistance training for elderly patients with a long history of type 2 diabetes. *J. Sports Sci. Med.* **2012**, *11*, 495–501.
143. Mitranun, W.; Deerochanawong, C.; Tanaka, H.; Suksom, D. Continuous vs interval training on glycemic control and macro- and microvascular reactivity in type 2 diabetic patients. *Scand. J. Med. Sci. Sports* **2014**, *24*, e69–e76. [[CrossRef](#)] [[PubMed](#)]
144. Chien, Y.H.; Tsai, C.J.; Wang, D.C.; Chuang, P.H.; Lin, H.T. Effects of 12-Week Progressive Sandbag Exercise Training on Glycemic Control and Muscle Strength in Patients with Type 2 Diabetes Mellitus Combined with Possible Sarcopenia. *Int. J. Environ. Res. Public Health* **2022**, *19*, 15009. [[CrossRef](#)] [[PubMed](#)]
145. Holtén, K.M.; Zacho, M.; Gaster, M.; Juel, C.; Wojtaszewski, F.P.J.; Dela, F. Strength Training Increases Insulin-Mediated Glucose Uptake, GLUT4 Content, and Insulin Signaling in Skeletal Muscle in Patients with Type 2 Diabetes. *Diabetes* **2004**, *53*, 294–305. [[CrossRef](#)] [[PubMed](#)]
146. Chen, H.T.; Chung, Y.C.; Chen, Y.J.; Ho, S.Y.; Wu, H.J. Effects of Different Types of Exercise on Body Composition, Muscle Strength, and IGF-1 in the Elderly with Sarcopenic Obesity. *J. Am. Geriatr. Soc.* **2017**, *65*, 827–832. [[CrossRef](#)] [[PubMed](#)]

147. Hovanec, N.; Sawant, A.; Overend, T.J.; Petrella, R.J.; Vandervoort, A.A. Resistance training and older adults with type 2 diabetes mellitus: Strength of the evidence. *J. Aging Res.* **2012**, *2012*, 284635. [[CrossRef](#)] [[PubMed](#)]
148. Pan, B.; Ge, L.; Xun, Y.Q.; Chen, Y.J.; Gao, C.Y.; Han, X.; Zuo, L.Q.; Shan, H.Q.; Yang, K.H.; Ding, G.W.; et al. Exercise training modalities in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. *Int. J. Behav. Nutr. Phys. Act.* **2018**, *15*, 72. [[CrossRef](#)]
149. Mesinovic, J.; Zengin, A.; De Courten, B.; Ebeling, P.R.; Scott, D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. *Diabetes Metab. Syndr. Obes.* **2019**, *12*, 1057–1072. [[CrossRef](#)]
150. Fulster, S.; Tacke, M.; Sandek, A.; Ebner, N.; Tschöpe, C.; Doehner, W.; Anker, S.D.; von Haehling, S. Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur. Heart J.* **2013**, *34*, 512–519. [[CrossRef](#)]
151. Suzuki, T.; Palus, S.; Springer, J. Skeletal muscle wasting in chronic heart failure. *ESC Heart Fail.* **2018**, *5*, 1099–1107. [[CrossRef](#)]
152. Fisher, S.; Smart, N.A.; Pearson, M.J. Resistance training in heart failure patients: A systematic review and meta-analysis. *Heart Fail. Rev.* **2022**, *27*, 1665–1682. [[CrossRef](#)]
153. Pu, T.C.; Johnson, T.M.; Forman, E.D.; Hausdorff, M.J.; Roubenoff, R.; Foldvari, M.; Fielding, A.R.; Fiatarone Singh, A.M. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. *J. Appl. Physiol.* **2001**, *90*, 2341–2350. [[CrossRef](#)]
154. Degache, F.; Garet, M.; Calmels, P.; Costes, F.; Bathelemy, J.C.; Roche, F. Enhancement of isokinetic muscle strength with a combined training programme in chronic heart failure. *Clin. Physiol. Funct. Imaging* **2007**, *27*, 225–230. [[CrossRef](#)]
155. Bouchla, A.; Karatzanos, E.; Dimopoulos, S.; Tasoulis, A.; Agapitou, V.; Diakos, N.; Tselioli, E.; Terrovitis, J.; Nanas, S. The addition of strength training to aerobic interval training: Effects on muscle strength and body composition in CHF patients. *J. Cardiopulm. Rehabil. Prev.* **2011**, *31*, 47–51. [[CrossRef](#)]
156. Bowen, T.S.; Rolim, N.P.; Fischer, T.; Baekkerud, F.H.; Medeiros, A.; Werner, S.; Bronstad, E.; Rognum, O.; Mangner, N.; Linke, A.; et al. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle. *Eur. J. Heart Fail.* **2015**, *17*, 263–272. [[CrossRef](#)] [[PubMed](#)]
157. Gielen, S.; Sandri, M.; Kozarez, I.; Kratzsch, J.; Teupser, D.; Thiery, J.; Erbs, S.; Mangner, N.; Lenk, K.; Hambrecht, R.; et al. Exercise Training Attenuates MuRF-1 Expression in the Skeletal Muscle of Patients with Chronic Heart Failure Independent of Age. *Circulation* **2012**, *125*, 2716–2727. [[CrossRef](#)] [[PubMed](#)]
158. Lenk, K.; Erbs, S.; Höllriegel, R.; Beck, E.; Linke, A.; Gielen, S.; Winkler, S.M.; Sandri, M.; Hambrecht, R.; Schuler, G.; et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. *Eur. J. Prev. Cardiol.* **2012**, *19*, 404–411. [[CrossRef](#)]
159. Saitoh, M.; Ishida, J.; Doehner, W.; von Haehling, S.; Anker, M.S.; Coats, A.J.S.; Anker, S.D.; Springer, J. Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. *Int. J. Cardiol.* **2017**, *238*, 5–11. [[CrossRef](#)]
160. Lira, V.A.; Benton, C.R.; Yan, Z.; Bonen, A. PGC-1 α regulation by exercise training and its influences on muscle function and insulin sensitivity. *Am. J. Physiol. Endocrinol. Metab.* **2010**, *299*, E145–E161. [[CrossRef](#)] [[PubMed](#)]
161. Lee, H.S.; Park, K.W.; Kang, J.; Ki, Y.J.; Chang, M.; Han, J.K.; Yang, H.M.; Kang, H.J.; Koo, B.K.; Kim, H.S. Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease. *J. Clin. Med.* **2020**, *9*, 3121. [[CrossRef](#)] [[PubMed](#)]
162. Xue, Q.; Wu, J.; Ren, Y.; Hu, J.; Yang, K.; Cao, J. Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease: A systematic review and meta-analysis. *BMC Geriatr.* **2021**, *21*, 493. [[CrossRef](#)] [[PubMed](#)]
163. Yamamoto, S.; Hotta, K.; Ota, E.; Mori, R.; Matsunaga, A. Effects of resistance training on muscle strength, exercise capacity, and mobility in middle-aged and elderly patients with coronary artery disease: A meta-analysis. *J. Cardiol.* **2016**, *68*, 125–134. [[CrossRef](#)] [[PubMed](#)]
164. Fan, Y.; Yu, M.; Li, J.; Zhang, H.; Liu, Q.; Zhao, L.; Wang, T.; Xu, H. Efficacy and Safety of Resistance Training for Coronary Heart Disease Rehabilitation: A Systematic Review of Randomized Controlled Trials. *Front. Cardiovasc. Med.* **2021**, *8*, 754794. [[CrossRef](#)] [[PubMed](#)]
165. Pizzimenti, M.; Meyer, A.; Charles, A.-L.; Giannini, M.; Chakfé, N.; Lejay, A.; Geny, B. Sarcopenia and peripheral arterial disease: A systematic review. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 866–886. [[CrossRef](#)]
166. McDermott, M.M.; Guralnik, J.M.; Albay, M.; Bandinelli, S.; Miniati, B.; Ferrucci, L. Impairments of muscles and nerves associated with peripheral arterial disease and their relationship with lower extremity functioning: The InCHIANTI Study. *J. Am. Geriatr. Soc.* **2004**, *52*, 405–410. [[CrossRef](#)] [[PubMed](#)]
167. McGuigan, M.R.; Bronks, R.; Newton, R.U.; Sharman, M.J.; Graham, J.C.; Cody, D.V.; Kraemer, W.J. Resistance training in patients with peripheral arterial disease: Effects on myosin isoforms, fiber type distribution, and capillary supply to skeletal muscle. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2001**, *56*, B302–B310. [[CrossRef](#)]
168. Parmenter, B.J.; Mavros, Y.; Ritti Dias, R.; King, S.; Fiatarone Singh, M. Resistance training as a treatment for older persons with peripheral artery disease: A systematic review and meta-analysis. *Br. J. Sports Med.* **2020**, *54*, 452–461.
169. Deutz, N.E.; Bauer, J.M.; Barazzoni, R.; Biolo, G.; Boirie, Y.; Bosy-Westphal, A.; Cederholm, T.; Cruz-Jentoft, A.; Krznaric, Z.; Nair, K.S.; et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. *Clin. Nutr.* **2014**, *33*, 929–936. [[CrossRef](#)]
170. Fry, C.S.; Rasmussen, B.B. Skeletal muscle protein balance and metabolism in the elderly. *Curr. Aging Sci.* **2011**, *4*, 260–268. [[CrossRef](#)]

171. Barazzoni, R.; Bischoff, S.; Boirie, Y.; Busetto, L.; Cederholm, T.; Dicker, D.; Toplak, H.; Van Gossum, A.; Yumuk, V.; Vettor, R. Sarcopenic obesity: Time to meet the challenge. *Obes. Facts* **2018**, *11*, 294–305. [[CrossRef](#)]
172. Cummings, S.; Parham, E.S.; Strain, G.W. Position of the American Dietetic Association Weight Management. *J. Am. Diet. Assoc.* **2002**, *102*, 1145–1155. [[CrossRef](#)]
173. Houston, D.K.; Nicklas, B.J.; Ding, J.; Harris, T.B.; Tylavsky, F.A.; Newman, A.B.; Lee, J.S.; Sahyoun, N.R.; Visser, M.; Kritchevsky, S.B.; et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: The Health, Aging, and Body Composition (Health ABC) Study. *Am. J. Clin. Nutr.* **2008**, *87*, 150–155. [[CrossRef](#)] [[PubMed](#)]
174. Kim, H.K.; Suzuki, T.; Saito, K.; Yoshida, H.; Kobayashi, H.; Kato, H.; Katayama, M. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: A randomized controlled trial. *J. Am. Geriatr. Soc.* **2012**, *60*, 16–23. [[CrossRef](#)] [[PubMed](#)]
175. Campbell, T.M.; Vallis, L.A. Predicting fat-free mass index and sarcopenia in assisted-living older adults. *Age* **2014**, *36*, 9674. [[CrossRef](#)] [[PubMed](#)]
176. Morris, S.; Cater, J.D.; Green, M.A.; Johnstone, A.M.; Brunstrom, J.M.; Stevenson, E.J.; Williams, E.A.; Corfe, B.M. Inadequacy of Protein Intake in Older UK Adults. *Geriatrics* **2020**, *5*, 6. [[CrossRef](#)]
177. Johnson, N.R.; Kotarsky, C.J.; Mahoney, S.J.; Sawyer, B.C.; Stone, K.A.; Byun, W.; Hackney, K.J.; Mitchell, S.; Stastny, S.N. Evenness of Dietary Protein Intake Is Positively Associated with Lean Mass and Strength in Healthy Women. *Nutr. Metab. Insights* **2022**, *15*, 11786388221101829. [[CrossRef](#)]
178. Marshall, R.N.; Smeuninx, B.; Morgan, P.T.; Breen, L. Nutritional Strategies to Offset Disuse-Induced Skeletal Muscle Atrophy and Anabolic Resistance in Older Adults: From Whole-Foods to Isolated Ingredients. *Nutrients* **2020**, *12*, 1533. [[CrossRef](#)]
179. Breen, L.; Stokes, K.A.; Churchward-Venne, T.A.; Moore, D.R.; Baker, S.K.; Smith, K.; Atherton, P.J.; Phillips, S.M. Two Weeks of Reduced Activity Decreases Leg Lean Mass and Induces “Anabolic Resistance” of Myofibrillar Protein Synthesis in Healthy Elderly. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 2604–2612. [[CrossRef](#)]
180. Witard, O.C.; Jackman, S.R.; Breen, L.; Smith, K.; Selby, A.; Tipton, K.D. Myofibrillar muscle protein synthesis rates subsequent to a meal in response to increasing doses of whey protein at rest and after resistance exercise. *Am. J. Clin. Nutr.* **2014**, *99*, 86–95. [[CrossRef](#)]
181. Yang, Y.; Breen, L.; Burd, N.A.; Hector, A.J.; Churchward-Venne, T.A.; Josse, A.R.; Tarnopolsky, M.A.; Phillips, S.M. Resistance exercise enhances myofibrillar protein synthesis with graded intakes of whey protein in older men. *Br. J. Nutr.* **2012**, *108*, 1780–1788. [[CrossRef](#)]
182. Butterworth, M.; Lees, M.; Harlow, P.; Hind, K.; Duckworth, L.; Ispoglou, T. Acute effects of essential amino acid gel-based and whey protein supplements on appetite and energy intake in older women. *Appl. Physiol. Nutr. Metab.* **2019**, *44*, 1141–1149. [[CrossRef](#)]
183. Lonnie, M.; Hooker, E.; Brunstrom, J.M.; Corfe, B.M.; Green, M.A.; Watson, A.W.; Williams, E.A.; Stevenson, E.J.; Penson, S.; Johnstone, A.M. Protein for Life: Review of Optimal Protein Intake, Sustainable Dietary Sources and the Effect on Appetite in Ageing Adults. *Nutrients* **2018**, *10*, 360. [[CrossRef](#)]
184. Yang, J.; Chi, Y.; Burkhardt, B.R.; Guan, Y.; Wolf, B.A. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. *Nutr. Rev.* **2010**, *68*, 270–279. [[CrossRef](#)] [[PubMed](#)]
185. Pedrosa, J.A.B.; Zampieri, T.T.; Donato, J. Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis. *Nutrients* **2015**, *7*, 3914–3937. [[CrossRef](#)] [[PubMed](#)]
186. Traylor, D.A.; Kamal, M.; Nunes, E.A.; Prior, T.; Gorissen, S.H.M.; Lees, M.; Gesel, F.; Lim, C.; Phillips, S.M. Consumption of High-Leucine-Containing Protein Bar Following Breakfast Impacts Aminoacidemia and Subjective Appetite in Older Persons. *Curr. Dev. Nutr.* **2021**, *5*, nzab080. [[CrossRef](#)] [[PubMed](#)]
187. Ispoglou, T.; Deighton, K.; King, R.F.; White, H.; Lees, M. Novel essential amino acid supplements enriched with L-leucine facilitate increased protein and energy intakes in older women: A randomised controlled trial. *Nutr. J.* **2017**, *16*, 75. [[CrossRef](#)] [[PubMed](#)]
188. Bolster, D.R.; Rahn, M.; Kamil, A.G.; Bristol, L.T.; Goltz, S.R.; Leidy, H.J.; Blaze Mt, M.; Nunez, M.A.; Guo, E.; Wang, J.; et al. Consuming Lower-Protein Nutrition Bars with Added Leucine Elicits Postprandial Changes in Appetite Sensations in Healthy Women. *J. Nutr.* **2018**, *148*, 693–701. [[CrossRef](#)] [[PubMed](#)]
189. Aquilani, R.; Opasich, C.; Gualco, A.; Verri, M.; Testa, A.; Pasini, E.; Viglio, S.; Iadarola, P.; Pastoris, O.; Dossena, M.; et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. *Eur. J. Heart Fail.* **2008**, *10*, 1127–1135. [[CrossRef](#)]
190. Boirie, Y.; Dangin, M.; Gachon, P.; Vasson, M.-P.; Maubois, J.-L.; Beaufrère, B. Slow and fast dietary proteins differently modulate postprandial protein accretion. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 14930–14935. [[CrossRef](#)]
191. Sun, L.; Yuan, J.-L.; Chen, Q.-C.; Xiao, W.-K.; Ma, G.-P.; Liang, J.-H.; Chen, X.-K.; Wang, S.; Zhou, X.-X.; Wu, H.; et al. Red meat consumption and risk for dyslipidaemia and inflammation: A systematic review and meta-analysis. *Front. Cardiovasc. Med.* **2022**, *9*, 996467. [[CrossRef](#)]
192. Song, M.; Fung, T.T.; Hu, F.B.; Willett, W.C.; Longo, V.D.; Chan, A.T.; Giovannucci, E.L. Association of Animal and Plant Protein Intake with All-Cause and Cause-Specific Mortality. *JAMA Intern. Med.* **2016**, *176*, 1453–1463. [[CrossRef](#)]

193. Budhathoki, S.; Sawada, N.; Iwasaki, M.; Yamaji, T.; Goto, A.; Kotemori, A.; Ishihara, J.; Takachi, R.; Charvat, H.; Mizoue, T. Association of animal and plant protein intake with all-cause and cause-specific mortality in a Japanese cohort. *JAMA Intern. Med.* **2019**, *179*, 1509–1518. [[CrossRef](#)] [[PubMed](#)]
194. Wang, M.; Wang, Z.; Lee, Y.; Lai, H.T.; de Oliveira Otto, M.C.; Lemaitre, R.N.; Fretts, A.; Sotoodehnia, N.; Budoff, M.; DiDonato, J.A. Dietary meat, trimethylamine N-oxide-related metabolites, and incident cardiovascular disease among older adults: The cardiovascular health study. *Arterioscler. Thromb. Vasc. Biol.* **2022**, *42*, e273–e288. [[CrossRef](#)] [[PubMed](#)]
195. Meng, S.J.; Yu, L.J. Oxidative stress, molecular inflammation and sarcopenia. *Int. J. Mol. Sci.* **2010**, *11*, 1509–1526. [[CrossRef](#)]
196. Sun, Y.; Rawish, E.; Nording, H.M.; Langer, H.F. Inflammation in Metabolic and Cardiovascular Disorders-Role of Oxidative Stress. *Life* **2021**, *11*, 672. [[CrossRef](#)] [[PubMed](#)]
197. Chen, M.; Wang, Y.; Deng, S.; Lian, Z.; Yu, K. Skeletal muscle oxidative stress and inflammation in aging: Focus on antioxidant and anti-inflammatory therapy. *Front. Cell Dev. Biol.* **2022**, *10*, 964130. [[CrossRef](#)] [[PubMed](#)]
198. Ferrucci, L.; Fabbri, E. Inflammaging: Chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* **2018**, *15*, 505–522. [[CrossRef](#)]
199. Baharirad, N.; Pasdar, Y.; Nachvak, M.; Ghavamzadeh, S.; Soroush, A.; Saber, A.; Mostafai, S.; Naghipour, A.; Abdollahzad, H. The relationship of dietary total antioxidant capacity with sarcopenia and cardiometabolic biomarkers in type 2 diabetes patients. *Physiol. Rep.* **2022**, *10*, e15190. [[CrossRef](#)] [[PubMed](#)]
200. Aune, D. Plant Foods, Antioxidant Biomarkers, and the Risk of Cardiovascular Disease, Cancer, and Mortality: A Review of the Evidence. *Adv. Nutr.* **2019**, *10*, S404–S421. [[CrossRef](#)]
201. Besora-Moreno, M.; Llauroad, E.; Valls, R.M.; Tarro, L.; Pedret, A.; Solà, R. Antioxidant-rich foods, antioxidant supplements, and sarcopenia in old-young adults ≥ 55 years old: A systematic review and meta-analysis of observational studies and randomized controlled trials. *Clin. Nutr.* **2022**, *41*, 2308–2324. [[CrossRef](#)]
202. van Dronkelaar, C.; van Velzen, A.; Abdelrazek, M.; van der Steen, A.; Weijis, P.J.M.; Tieland, M. Minerals and Sarcopenia; The Role of Calcium, Iron, Magnesium, Phosphorus, Potassium, Selenium, Sodium, and Zinc on Muscle Mass, Muscle Strength, and Physical Performance in Older Adults: A Systematic Review. *J. Am. Med. Dir. Assoc.* **2018**, *19*, 6–11. [[CrossRef](#)]
203. Linton, C.; Wright, H.H.; Wadsworth, D.P.; Schaumberg, M.A. Dietary Inflammatory Index and Associations with Sarcopenia Symptomology in Community-Dwelling Older Adults. *Nutrients* **2022**, *14*, 5319. [[CrossRef](#)]
204. Chareh, N.; Kiesswetter, E.; Kob, R.; Hannink, A.; Brandl, B.; Skurk, T.; Hauner, H.; Sieber, C.C.; Volkert, D. Association Between Inflammation and Appetite in Healthy Community-Dwelling Older Adults-An enable Study. *Front. Aging* **2022**, *3*, 826816. [[CrossRef](#)]
205. Silva, F.O.C.d.; Macedo, D.V. Physical exercise, inflammatory process and adaptive condition: An overview. *Rev. Bras. Cineantropometria Desempenho Hum.* **2011**, *13*, 320–328.
206. Bjørnsen, T.; Salvesen, S.; Berntsen, S.; Hetlelid, K.; Stea, T.; Lohne-Seiler, H.; Rohde, G.; Haraldstad, K.; Raastad, T.; Kjøpp, U. Vitamin C and E supplementation blunts increases in total lean body mass in elderly men after strength training. *Scand. J. Med. Sci. Sports* **2016**, *26*, 755–763. [[CrossRef](#)] [[PubMed](#)]
207. Martínez-Ferrán, M.; Berlanga, L.A.; Barcelo-Guido, O.; Matos-Duarte, M.; Vicente-Campos, D.; Sánchez-Jorge, S.; Romero-Morales, C.; Munguía-Izquierdo, D.; Pareja-Galeano, H. Antioxidant vitamin supplementation on muscle adaptations to resistance training: A double-blind, randomized controlled trial. *Nutrition* **2023**, *105*, 111848. [[CrossRef](#)] [[PubMed](#)]
208. Alway, S.E.; McCrory, J.L.; Kearcher, K.; Vickers, A.; Frear, B.; Gilleland, D.L.; Bonner, D.E.; Thomas, J.M.; Donley, D.A.; Lively, M.W. Resveratrol enhances exercise-induced cellular and functional adaptations of skeletal muscle in older men and women. *J. Gerontol. Ser. A Biomed. Sci. Med. Sci.* **2017**, *72*, 1595–1606. [[CrossRef](#)] [[PubMed](#)]
209. Dupont, J.; Dedeyne, L.; Dalle, S.; Koppo, K.; Gielen, E. The role of omega-3 in the prevention and treatment of sarcopenia. *Aging Clin. Exp. Res.* **2019**, *31*, 825–836. [[CrossRef](#)]
210. Okamura, T.; Hashimoto, Y.; Miki, A.; Kaji, A.; Sakai, R.; Iwai, K.; Osaka, T.; Ushigome, E.; Hamaguchi, M.; Yamazaki, M. Reduced dietary omega-3 fatty acids intake is associated with sarcopenia in elderly patients with type 2 diabetes: A cross-sectional study of KAMOGAWA-DM cohort study. *J. Clin. Biochem. Nutr.* **2020**, *66*, 233–237. [[CrossRef](#)]
211. Hu, Y.; Hu, F.B.; Manson, J.E. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. *J. Am. Heart Assoc.* **2019**, *8*, e013543. [[CrossRef](#)]
212. Ma, M.Y.; Li, K.L.; Zheng, H.; Dou, Y.L.; Han, L.Y.; Wang, L. Omega-3 index and type 2 diabetes: Systematic review and meta-analysis. *Prostaglandins Leukot. Essent. Fatty Acids* **2021**, *174*, 102361. [[CrossRef](#)]
213. Park, K.; Ahn, C.W.; Kim, Y.; Nam, J.S. The effect of Korean Red Ginseng on sarcopenia biomarkers in type 2 diabetes patients. *Arch. Gerontol. Geriatr.* **2020**, *90*, 104108. [[CrossRef](#)] [[PubMed](#)]
214. Kim, H.; Kim, M.; Kojima, N.; Fujino, K.; Hosoi, E.; Kobayashi, H.; Somekawa, S.; Niki, Y.; Yamashiro, Y.; Yoshida, H. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: A randomized controlled trial. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 1011–1019. [[CrossRef](#)] [[PubMed](#)]
215. Holick, M.F.; Chen, T.C. Vitamin D deficiency: A worldwide problem with health consequences. *Am. J. Clin. Nutr.* **2008**, *87*, 1080S–1086S. [[CrossRef](#)]
216. Van der Wielen, R.P.; De Groot, L.; Van Staveren, W.; Löwik, M.; Van den Berg, H.; Haller, J.; Moreiras, O. Serum vitamin D concentrations among elderly people in Europe. *Lancet* **1995**, *346*, 207–210. [[CrossRef](#)] [[PubMed](#)]

217. Kupisz-Urbańska, M.; Płudowski, P.; Marcinowska-Suchowierska, E. Vitamin d deficiency in older patients—Problems of sarcopenia, drug interactions, management in deficiency. *Nutrients* **2021**, *13*, 1247. [[CrossRef](#)]
218. Uchitomi, R.; Oyabu, M.; Kamei, Y. Vitamin D and sarcopenia: Potential of vitamin D supplementation in sarcopenia prevention and treatment. *Nutrients* **2020**, *12*, 3189. [[CrossRef](#)] [[PubMed](#)]
219. Park, J.E.; Pichiah, P.T.; Cha, Y.-S. Vitamin D and metabolic diseases: Growing roles of vitamin D. *J. Obes. Metab. Syndr.* **2018**, *27*, 223. [[CrossRef](#)]
220. Remelli, F.; Vitali, A.; Zurlo, A.; Volpato, S. Vitamin D deficiency and sarcopenia in older persons. *Nutrients* **2019**, *11*, 2861. [[CrossRef](#)]
221. Cereda, E.; Pisati, R.; Rondanelli, M.; Caccialanza, R. Whey protein, leucine-and vitamin-D-enriched oral nutritional supplementation for the treatment of sarcopenia. *Nutrients* **2022**, *14*, 1524. [[CrossRef](#)]
222. Di Filippo, L.; Allora, A.; Doga, M.; Formenti, A.M.; Locatelli, M.; Rovere Querini, P.; Frara, S.; Giustina, A. Vitamin D levels are associated with blood glucose and BMI in COVID-19 patients, predicting disease severity. *J. Clin. Endocrinol. Metab.* **2022**, *107*, e348–e360. [[CrossRef](#)]
223. Saitoh, M.; Ebner, N.; von Haehling, S.; Anker, S.D.; Springer, J. Therapeutic considerations of sarcopenia in heart failure patients. *Expert Rev. Cardiovasc. Ther.* **2018**, *16*, 133–142. [[CrossRef](#)] [[PubMed](#)]
224. Dawson-Hughes, B.; Mithal, A.; Bonjour, J.-P.; Boonen, S.; Burckhardt, P.; Fuleihan, G.-H.; Josse, R.; Lips, P.; Morales-Torres, J.; Yoshimura, N. IOF position statement: Vitamin D recommendations for older adults. *Osteoporos. Int.* **2010**, *21*, 1151–1154. [[CrossRef](#)]
225. Prokopidis, K.; Cervo, M.M.; Gandham, A.; Scott, D. Impact of protein intake in older adults with sarcopenia and obesity: A gut microbiota perspective. *Nutrients* **2020**, *12*, 2285. [[CrossRef](#)] [[PubMed](#)]
226. Ticinesi, A.; Nouvenne, A.; Cerundolo, N.; Catania, P.; Prati, B.; Tana, C.; Meschi, T. Gut microbiota, muscle mass and function in aging: A focus on physical frailty and sarcopenia. *Nutrients* **2019**, *11*, 1633. [[CrossRef](#)]
227. Goma, E.Z. Human gut microbiota/microbiome in health and diseases: A review. *Antonie Van. Leeuwenhoek* **2020**, *113*, 2019–2040. [[CrossRef](#)] [[PubMed](#)]
228. Daily, J.W.; Park, S. Sarcopenia is a cause and consequence of metabolic dysregulation in aging humans: Effects of gut dysbiosis, glucose dysregulation, diet and lifestyle. *Cells* **2022**, *11*, 338. [[CrossRef](#)] [[PubMed](#)]
229. Liu, C.; Cheung, W.H.; Li, J.; Chow, S.K.H.; Yu, J.; Wong, S.H.; Ip, M.; Sung, J.J.Y.; Wong, R.M.Y. Understanding the gut microbiota and sarcopenia: A systematic review. *J. Cachexia Sarcopenia Muscle* **2021**, *12*, 1393–1407. [[CrossRef](#)]
230. Prokopidis, K.; Chambers, E.; Ni Lochlainn, M.; Witard, O.C. Mechanisms linking the gut-muscle axis with muscle protein metabolism and anabolic resistance: Implications for older adults at risk of sarcopenia. *Front. Physiol.* **2021**, *12*, 1910. [[CrossRef](#)]
231. Picca, A.; Ponziani, F.R.; Calvani, R.; Marini, F.; Biancolillo, A.; Coelho-Júnior, H.J.; Gervasoni, J.; Primiano, A.; Putignano, L.; Del Chierico, F. Gut microbial, inflammatory and metabolic signatures in older people with physical frailty and sarcopenia: Results from the BIOSPHERE study. *Nutrients* **2019**, *12*, 65. [[CrossRef](#)]
232. Ticinesi, A.; Mancabelli, L.; Tagliaferri, S.; Nouvenne, A.; Milani, C.; Del Rio, D.; Lauretani, F.; Maggio, M.G.; Ventura, M.; Meschi, T. The gut-muscle axis in older subjects with low muscle mass and performance: A proof of concept study exploring fecal microbiota composition and function with shotgun metagenomics sequencing. *Int. J. Mol. Sci.* **2020**, *21*, 8946. [[CrossRef](#)]
233. Salazar, N.; Arbolea, S.; Fernández-Navarro, T.; de Los Reyes-Gavilán, C.G.; Gonzalez, S.; Gueimonde, M. Age-associated changes in gut microbiota and dietary components related with the immune system in adulthood and old age: A cross-sectional study. *Nutrients* **2019**, *11*, 1765. [[CrossRef](#)] [[PubMed](#)]
234. Sánchez y Sánchez de la Barquera, B.; Martínez Carrillo, B.; Aguirre Garrido, J.; Martínez Mendez, R.; Benitez Arciniega, A.; Valdes Ramos, R.; Soto Piña, A.E. Emerging Evidence on the Use of Probiotics and Prebiotics to Improve the Gut Microbiota of Older Adults with Frailty Syndrome: A Narrative Review. *J. Nutr. Health Aging* **2022**, *26*, 926–935. [[CrossRef](#)] [[PubMed](#)]
235. Prokopidis, K.; Giannos, P.; Kirwan, R.; Ispoglou, T.; Galli, F.; Witard, O.C.; Triantafyllidis, K.K.; Kechagias, K.S.; Morwani-Manghani, J.; Ticinesi, A.; et al. Impact of probiotics on muscle mass, muscle strength and lean mass: A systematic review and meta-analysis of randomized controlled trials. *J. Cachexia Sarcopenia Muscle* **2022**, *14*, 30–44. [[CrossRef](#)]
236. Beudart, C.; Dawson, A.; Shaw, S.C.; Harvey, N.C.; Kanis, J.A.; Binkley, N.; Reginster, J.Y.; Chapurlat, R.; Chan, D.C.; Bruyère, O.; et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: Systematic review. *Osteoporos. Int.* **2017**, *28*, 1817–1833. [[CrossRef](#)]
237. Kirkman, D.L.; Lee, D.C.; Carbone, S. Resistance exercise for cardiac rehabilitation. *Prog. Cardiovasc. Dis.* **2022**, *70*, 66–72. [[CrossRef](#)] [[PubMed](#)]
238. Bull, F.C.; Al-Ansari, S.S.; Biddle, S.; Borodulin, K.; Buman, M.P.; Cardon, G.; Carty, C.; Chaput, J.-P.; Chastin, S.; Chou, R.; et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br. J. Sport. Med.* **2020**, *54*, 1451–1462. [[CrossRef](#)]
239. Gibson-Moore, H. UK Chief Medical Officers’ physical activity guidelines 2019: What’s new and how can we get people more active? *Nutr. Bull.* **2019**, *44*, 320–328. [[CrossRef](#)]
240. Gluchowski, A.; Bilsborough, H.; McDermott, J.; Hawley-Hague, H.; Todd, C. ‘A Lot of People Just Go for Walks, and Don’t Do Anything Else’: Older Adults in the UK Are Not Aware of the Strength Component Embedded in the Chief Medical Officers’ Physical Activity Guidelines—A Qualitative Study. *Int. J. Environ. Res. Public Health* **2022**, *19*, 10002. [[CrossRef](#)]

241. Chartered Society of Physiotherapy. Strength Messaging Insight Report. Available online: <https://www.csp.org.uk/publications/strength-messaging-insight-report> (accessed on 1 March 2023).
242. Beasley, J.M.; Shikany, J.M.; Thomson, C.A. The role of dietary protein intake in the prevention of sarcopenia of aging. *Nutr. Clin. Pract.* **2013**, *28*, 684–690. [[CrossRef](#)]
243. Welch, A.A. Nutritional influences on age-related skeletal muscle loss. *Proc. Nutr. Soc.* **2014**, *73*, 16–33. [[CrossRef](#)]
244. Patel, A.; Schofield, G.M.; Kolt, G.S.; Keogh, J.W. Perceived barriers, benefits, and motives for physical activity: Two primary-care physical activity prescription programs. *J. Aging Phys. Act.* **2013**, *21*, 85–99. [[CrossRef](#)] [[PubMed](#)]
245. Bäck, M.; Cider, Å.; Herlitz, J.; Lundberg, M.; Jansson, B. The impact on kinesiophobia (fear of movement) by clinical variables for patients with coronary artery disease. *Int. J. Cardiol.* **2013**, *167*, 391–397. [[CrossRef](#)] [[PubMed](#)]
246. Gray, M.; Butler, K. Preventing weakness and stiffness—A top priority for health and social care. *Best. Pract. Res. Clin. Rheumatol.* **2017**, *31*, 255–259. [[CrossRef](#)] [[PubMed](#)]
247. Lee, L.-L.; Arthur, A.; Avis, M. Using self-efficacy theory to develop interventions that help older people overcome psychological barriers to physical activity: A discussion paper. *Int. J. Nurs. Stud.* **2008**, *45*, 1690–1699. [[CrossRef](#)] [[PubMed](#)]
248. Boulton, E.; Hawley-Hague, H.; French, D.P.; Mellone, S.; Zacchi, A.; Clemson, L.; Vereijken, B.; Todd, C. Implementing behaviour change theory and techniques to increase physical activity and prevent functional decline among adults aged 61–70: The PreventIT project. *Prog. Cardiovasc. Dis.* **2019**, *62*, 147–156. [[CrossRef](#)] [[PubMed](#)]
249. Mukherji, A.B.; Lu, D.; Qin, F.; Hedlin, H.; Johannsen, N.M.; Chung, S.; Kobayashi, Y.; Haddad, F.; Lamendola, C.; Basina, M.; et al. Effectiveness of a Community-Based Structured Physical Activity Program for Adults with Type 2 Diabetes: A Randomized Clinical Trial. *JAMA Netw. Open* **2022**, *5*, e2247858. [[CrossRef](#)]
250. Dyson, J.; Cowdell, F. How is the Theoretical Domains Framework applied in designing interventions to support healthcare practitioner behaviour change? A systematic review. *Int. J. Qual. Health Care* **2021**, *33*, mzab106. [[CrossRef](#)]
251. Morgan, F.; Battersby, A.; Weightman, A.L.; Searchfield, L.; Turley, R.; Morgan, H.; Jagroo, J.; Ellis, S. Adherence to exercise referral schemes by participants—What do providers and commissioners need to know? A systematic review of barriers and facilitators. *BMC Public Health* **2016**, *16*, 227. [[CrossRef](#)]
252. Mazeas, A.; Duclos, M.; Pereira, B.; Chalabaev, A. Evaluating the Effectiveness of Gamification on Physical Activity: Systematic Review and Meta-analysis of Randomized Controlled Trials. *J. Med. Internet Res.* **2022**, *24*, e26779. [[CrossRef](#)]
253. Perski, O.; Keller, J.; Kale, D.; Asare, B.Y.-A.; Schneider, V.; Powell, D.; Naughton, F.; ten Hoor, G.; Verboon, P.; Kwasnicka, D. Understanding health behaviours in context: A systematic review and meta-analysis of ecological momentary assessment studies of five key health behaviours. *Health Psychol. Rev.* **2022**, *16*, 576–601. [[CrossRef](#)]
254. Reid, H.; Caterson, J.; Smith, R.; Baldock, J.; Jones, N.; Copeland, R. What do healthcare professionals want from a resource to support person-centred conversations on physical activity? A mixed-methods, user-centric approach to developing educational resources. *BMJ Open Sport Exerc. Med.* **2022**, *8*, e001280. [[CrossRef](#)] [[PubMed](#)]
255. Robinson, R.; Crank, H.; Humphreys, H.; Fisher, P.; Greenfield, D.M. Allied health professional’s self-reported competences and confidence to deliver physical activity advice to cancer patients at a single Centre in England. *Disabil. Rehabil.* **2022**, *27*, 1–7. [[CrossRef](#)] [[PubMed](#)]
256. Shore, C.B.; Galloway, S.D.R.; Gorely, T.; Hunter, A.M.; Hubbard, G. Exercise Referral Instructors’ Perspectives on Supporting and Motivating Participants to Uptake, Attend and Adhere to Exercise Prescription: A Qualitative Study. *Int. J. Environ. Res. Public Health* **2021**, *19*, 203. [[CrossRef](#)]
257. Chater, N.; Loewenstein, G. The i-frame and the s-frame: How focusing on individual-level solutions has led behavioral public policy astray. *Behav. Brain Sci.* **2022**, *5*, 1–60. [[CrossRef](#)]
258. Lin, T.-R.; Huang, X.-Y.; Hwu, C.-M. Exercise Experiences of Older Adults with Diabetes and Sarcopenia: A Phenomenological Study. *Clin. Nurs. Res.* **2021**, *31*, 292–300. [[CrossRef](#)] [[PubMed](#)]
259. van den Helder, J.; Mehra, S.; van Dronkelaar, C.; Ter Riet, G.; Tieland, M.; Visser, B.; Kröse, B.J.A.; Engelbert, R.H.H.; Weijs, P.J.M. Blended home-based exercise and dietary protein in community-dwelling older adults: A cluster randomized controlled trial. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 1590–1602. [[CrossRef](#)]
260. Craig, P.; Dieppe, P.; Macintyre, S.; Michie, S.; Nazareth, I.; Petticrew, M. Developing and evaluating complex interventions: The new Medical Research Council guidance. *BMJ* **2008**, *337*, a1655. [[CrossRef](#)]
261. Mehra, S.; Visser, B.; Dadema, T.; van den Helder, J.; Engelbert, R.H.; Weijs, P.J.; Kröse, B.J. Translating behavior change principles into a blended exercise intervention for older adults: Design study. *JMIR Res. Protoc.* **2018**, *7*, e9244. [[CrossRef](#)]
262. Michie, S.; Richardson, M.; Johnston, M.; Abraham, C.; Francis, J.; Hardeman, W.; Eccles, M.P.; Cane, J.; Wood, C.E. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an international consensus for the reporting of behavior change interventions. *Ann. Behav. Med.* **2013**, *46*, 81–95. [[CrossRef](#)]
263. Rhodes, R.E.; McEwan, D.; Rebar, A.L. Theories of physical activity behaviour change: A history and synthesis of approaches. *Psychol. Sport Exerc.* **2019**, *42*, 100–109. [[CrossRef](#)]
264. Segar, M.L.; Guérin, E.; Phillips, E.; Fortier, M. From a vital sign to vitality: Selling exercise so patients want to buy it. *Curr. Sports Med. Rep.* **2016**, *15*, 276–281. [[CrossRef](#)] [[PubMed](#)]
265. van Dulmen, S.; Sluijs, E.; Van Dijk, L.; de Ridder, D.; Heerdink, R.; Bensing, J. Patient adherence to medical treatment: A review of reviews. *BMC Health Serv. Res.* **2007**, *7*, 55. [[CrossRef](#)] [[PubMed](#)]

266. Organisation for Economic Co-Operation and Development (OECD). *Behavioural Insights and Public Policy*; Organisation for Economic Co-operation and Development (OECD): Paris, France, 2017.
267. Milkman, K.L.; Gromet, D.; Ho, H.; Kay, J.S.; Lee, T.W.; Pandiloski, P.; Park, Y.; Rai, A.; Bazerman, M.; Beshears, J.; et al. Megastudies improve the impact of applied behavioural science. *Nature* **2021**, *600*, 478–483. [[CrossRef](#)]
268. Robertson, S.; Zwolinsky, S.; Pringle, A.; McKenna, J.; Daly-Smith, A.; White, A. 'It is fun, fitness and football really': A process evaluation of a football-based health intervention for men. *Qual. Res. Sport Exerc. Health* **2013**, *5*, 419–439. [[CrossRef](#)]
269. Geraedts, H.; Zijlstra, A.; Bulstra, S.K.; Stevens, M.; Zijlstra, W. Effects of remote feedback in home-based physical activity interventions for older adults: A systematic review. *Patient Educ. Couns.* **2013**, *91*, 14–24. [[CrossRef](#)] [[PubMed](#)]
270. Bizhanova, Z.; Sereika, S.M.; Brooks, M.M.; Rockette-Wagner, B.; Kariuki, J.K.; Burke, L.E. Identifying Predictors of Adherence to the Physical Activity Goal: A Secondary Analysis of the SMARTER Weight Loss Trial. *Med. Sci. Sports Exerc.* **2022**, *55*, 855–864. [[CrossRef](#)] [[PubMed](#)]
271. Tummers, S.; Hommersom, A.; Lechner, L.; Bemelmans, R.; Bolman, C.A.W. Determinants of physical activity behaviour change in (online) interventions, and gender-specific differences: A Bayesian network model. *Int. J. Behav. Nutr. Phys. Act.* **2022**, *19*, 155. [[CrossRef](#)]
272. Dickens, A.P.; Richards, S.H.; Greaves, C.J.; Campbell, J.L. Interventions targeting social isolation in older people: A systematic review. *BMC Public Health* **2011**, *11*, 647. [[CrossRef](#)]
273. Bailey, D.P.; Kilbride, C.; Harper, J.H.; Victor, C.; Brierley, M.L.; Hewson, D.J.; Chater, A.M. The Frail-LESS (LEss Sitting and Sarcopenia in Frail older adults) intervention to improve sarcopenia and maintain independent living via reductions in prolonged sitting: A randomised controlled feasibility trial protocol. *Pilot. Feasibility Stud.* **2023**, *9*, 1. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.